  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  1 
  
  
PROTOCOL TITLE  
A Multicenter , Single -Dose, Multiple -Dose, Randomized, Double -Blind, Placebo -Controlled 
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally 
Administered ENT -01 for the Treatment of Parkinson’s Disease  related Constipation.   IND# 
130770  
 
PROTOCOL NUMBER  
ENT -01 
 
STUDY PHASE  
Phase 1/2a  
 
 
 
 
 
 
 
 
 
Date issued:  10 April 2017  
Date Amended:   27 July 2017  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  2 
 PROTOCOL / AMENDMENT APPROVAL PAGES(S)  
  
Authored by:  [CONTACT_15957]-Authored by:  
  
[CONTACT_273723]  
[PHONE_5677]   [PHONE_5678]   
Telephone Number  Telephone Number  
[EMAIL_5352]   [EMAIL_5353]   
E-mail Address  E-mail Address  
    
Date  Date  
  
  
  
 
IMPORTANT CONTACTS A T ENTERIN  
 
Person responsible for this study  Telephone  E-mail address  
Denise Barbut  [PHONE_5679]  [EMAIL_5352]  
Michael Zasloff  [PHONE_5680]  [EMAIL_5353]  
Matt Lowery  [PHONE_5681]  [EMAIL_5354]   
Tom Malloy  [PHONE_5682]  [EMAIL_5355]   
 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  3 
 STUDY SYNOPSIS  
 
Study Title  Safety , Tolerability, Phar macokinetic and Pharmacodynamic 
characteristics  of single or multiple dose oral ENT -01 for 
Constipation in Parkinson’s Disease.  
Objectives  Stage  1: 
Primary Objective :  
Safety and  Tolerability of single oral doses  of ENT -01 in patients 
with Parkinson’s Disease related  constipation . 
Secondary objective:  
To evaluate the Pharmacokinetic (PK) characteristics of single 
oral doses of ENT -01 in patients with  Parkinson’s Disease  and 
constipation.  
 Stage  2: 
Primary objective:  
To determine the Safety, Tolerability , PK and Pharmacodynamic 
(PD) characteristics of repeated oral doses of ENT -01 in patients 
with Parkinson’s Disease  related  constipation.  
 
 Exploratory  
To determine the effectiveness of study drug in improving 
colonic  motility . 
To collect information on the e ffect of study drug on Quality of 
Life Measures  
Study Description  Multicenter, Single dose, Multi ple dose safety, tolerability and 
dose-finding  study leading into a Randomized, Doub le-blind, 
Placebo -controlled Study  
Study Population  Parkinson’s disease with constipation   
Study  Drug 
Administration  Oral 
Study Procedures  Colonic motility will be determined by [CONTACT_273724]1001  v0.9,  Version Date: 27JUL2017  4 
 Study Endpoints  Stage  1: 
Safety  Endpoint :  
Adverse events  as evaluated with patient report, vital signs, 
chemical chemistry and EKG  
Tolerability Endpoint:  
• Recurrent vomiting  
• Recurrent diarrhea  
• Abdominal pain  
• Postural hypotension/dizziness  
 Stage  2: 
Primary Efficacy Endpoint:   
• Bowel function as determined by [CONTACT_273725]  
• Colonic motility as determined by [CONTACT_273726]  
• Sleep diary  
• Skin temperature  (I-Button )-assessed sleep parameters  
• Mood assessed with Beck depressio n inventory  (BDI)  
• QOL, non -motor symptoms questionnaires  
Initial Date  March 2017  
Completion Date  December 2017  
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  5 
 TABLE O F CONTENTS  
1 INTRODUCTION ................................ ................................ ................................ ....... 10 
1.1 Background  ................................ ................................ ................................ ...... 10 
1.2 Rationale for the Study  ................................ ................................ ...................  12 
1.3 ENT -01 Dosing Rationale  ................................ ................................ ...............  15 
2 OBJECTIVES  ................................ ................................ ................................ .............  17 
2.1 Stage 1  ................................ ................................ ................................ ...............  18 
2.2 Stage 2  ................................ ................................ ................................ ...............  19 
3 STUDY DESCRIPTION  ................................ ................................ ............................  22 
3.1 Periods  ................................ ................................ ................................ ..............  23 
4 STUDY POPULATION  ................................ ................................ .............................  38 
4.1 Number of Patients  ................................ ................................ ..........................  38 
4.2 Selection Criteria  ................................ ................................ .............................  38 
4.3 Inclusion Criteria  ................................ ................................ ............................  38 
4.4 Exclusion Criteria  ................................ ................................ ............................  40 
4.5 Discontinuation Criteria  ................................ ................................ .................  41 
4.6 Concomitant Medication  ................................ ................................ ................  42 
5 STRATIFICATION AND  RANDOMIZATION (STAG E 2) ................................ . 43 
6 UNBLINDING ................................ ................................ ................................ .............  43 
7 MATERIALS  ................................ ................................ ................................ ..............  43 
7.1 Study Drug  ................................ ................................ ................................ ....... 43 
7.2 Packaging and Labeling  ................................ ................................ ..................  43 
7.3 Storage, Dispensing and Reconciliation of Study Drug  ...............................  43 
8 WARNINGS AND PRECAUT IONS  ................................ ................................ ........  44 
9 STUDY PROCEDURES  ................................ ................................ ............................  44 
9.1 Sitzmarks assessment of colonic motility in Stage 2  ................................ ..... 44 
9.2 Observations and Measurements  ................................ ................................ ... 45 
9.3 Informed Consent  ................................ ................................ ............................  45 
9.4 Instructions to Patients  ................................ ................................ ...................  45 
9.5 Clinical Laboratory Procedures  ................................ ................................ ..... 46 
9.6 Other Procedures  ................................ ................................ ............................  46 
9.7 CTCAE Definitions of Dose Limiting Adverse Events  ................................  47 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  6 
 9.8 Criteria for DLT Endpoints:  ................................ ................................ ..........  48 
9.9 Pre-Existing Medical Conditions  ................................ ................................ ... 48 
9.10  Treatment Emergent Adverse events  ................................ ............................  48 
9.11  Laboratory Abnormalities  ................................ ................................ ..............  49 
9.12  AE Assessment and Recording  ................................ ................................ ....... 49 
9.13  Reporting Requirements  ................................ ................................ .................  51 
9.14  Serious Adverse Events  ................................ ................................ ...................  52 
9.15  Notification of Serious Adverse Events  ................................ .........................  53 
9.16  Reporting a Serious Adverse Event  ................................ ...............................  53 
9.17  Serious  Adverse Experiences: After Study Participation  ............................  [ADDRESS_334342]  .........................  56 
9.21  Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ . 56 
9.22  Follow -Up and Final Reports  ................................ ................................ .........  56 
9.23  Regulatory Aspects  ................................ ................................ ..........................  56 
10 DATA MANAGEMENT AND STATISTICS  ................................ ..........................  57 
10.1  Sample Size/Power Considerations  ................................ ................................  57 
10.1.1  Stage 1  ................................ ................................ ................................ ...............  57 
10.1.2  Stage 2  ................................ ................................ ................................ ...............  58 
10.2  Data Collection and Case Report Form Monitoring  ................................ .... 59 
10.3  Endpoint definitions and measurements  ................................ .......................  59 
10.3.1  Assessment of Safety  ................................ ................................ .......................  59 
10.3.2  Efficacy Endpoints  ................................ ................................ ..........................  61 
10.4  Analysis Plan  ................................ ................................ ................................ .... 62 
10.5  Stage 2  ................................ ................................ ................................ ...............  62 
11 ESTIMATED DURATION O F THE STUDY  ................................ .........................  64 
12 ADMINISTRATIVE PROCE DURES AND ETHICAL CO NSIDERATIONS  ... 64 
12.1  Medical Care  ................................ ................................ ................................ .... 64 
12.2  Patient Information and Informed Consent  ................................ .................  64 
12.3  Study Monitoring  ................................ ................................ ............................  64 
12.4  Audits and Inspections  ................................ ................................ ....................  65 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334343] keepi[INVESTIGATOR_007]  ................................ ................................ . 69 
12.13  Inspection of Records  ................................ ................................ ......................  69 
12.14  Data Management  ................................ ................................ ...........................  69 
12.15  Data Capture and Management  ................................ ................................ ..... 69 
12.16  Liability and Insurance  ................................ ................................ ...................  70 
12.17  Retention of Records  ................................ ................................ .......................  70 
12.18  Data Quality Assurance  ................................ ................................ ..................  70 
13 USE OF INFORMATION  ................................ ................................ .........................  71 
14 INVESTIGATOR AGREEME NT ................................ ................................ ............  71 
15 REFERENCES  ................................ ................................ ................................ ............  72 
APPENDIX 1:  CLINICAL LABORATORY DETERMINATION  ................................ .. 75 
APPENDIX 2 : SCHEDULE OF EVENTS  ................................ ................................ ........  76 
APPENDIX 3 : NUMERIC RATING SCA LES FOR PAIN AND SWE LLING  ............  1 
APPE NDIX 4 : ROME -IV CRITERIA FOR CONSTIPATION  ................................ ...... 2 
APPENDIX 5 : EASE OF EVACUATION SCALE  ................................ ............................  3 
APPENDIX 6 : BRISTOL STOOL CHART  ................................ ................................ ........  4 
APPENDIX 7 : SLEEP DIARY  ................................ ................................ ..............................  5 
APPENDIX 8 : I-BUTTON  ................................ ................................ ................................ ....... 6 
APPENDIX 9 : NON -MOTOR SYMPTOMS QUESTIONNAIRE (NMSQ)  ......................  8 
APPENDIX 10 : BECK DEPRESSION INVENTORY (BDI)  ................................ ...........  9 
APPENDIX 11 : UNIFIED PARKINSON’S DISEASE RATING SCALE  ...................  14 
APPENDIX 12 : MINI MENTAL STATE EXAMINATION  ................................ ..........  43 
APPENDIX 13 : TRAIL MAKING A & B  ................................ ................................ ............  44 
APPENDIX 14 : UM -PDHQ  ................................ ................................ ................................ . 47 
APPENDIX 15 : PARKINSON’S DISEASE FATIGUE SCALE (PFS -16) ...................  49 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  8 
 APPENDIX 16 : PATIENT ASSESSMENT O F CONSTIPATION SYMPT OMS  ...... 51 
APPENDIX 17 : PATIENT ASSESSMENT O F CONSTIPATION QUALI TY OF LIFE
 ................................ ................................ ................................ ...........................  52 
APPENDIX 18 : REM SLEEP BEHAVIOR  DISORDER SCREENING 
QUESTIONNAIRE  ................................ ................................ ........................  55 
APPENDIX 19 : PARKINSON’S DISEASE SLEEP SCALE  ................................ .........  56 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334344] Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  Dose Limiting  Tolerability  
EMEA  European Agency for the Evaluation of Medicinal Products  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
IB Investigator’s Brochure  
ICF Informed Consent Form  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
ITT Intent to Treat  
MMSE  Mini Mental State Examination  
MTD  Maximum Tolerable Dose  
NMSQ  Non-Motor Symptom Questionnaire  
PAC -QOL  Patient Assessment of Constipation - Quality of Li fe 
PAC -SYM  Patient Assessment of Constipation Symptoms  
PDSS  Parkinson’s Disease Sleep Scale  
PFS Parkinson's Disease Fatigue Scale  
RBDQ  REM Sleep Behavior Disorder Questionnaire  
SAE  Serious Adverse Event  
TEAE  Treatment Emergent Adverse Event  
ULN  Upper Limit of Normal  
UM-PDHQ  University of Miami Parki nson’s Disease Hallucination  Questionnaire  
UPDRS  Unified Parkinson Disease Rating Scale  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  10 
 WHO  World Health  Organization  
1 INTRODUCTION  
Constipation is a common problem  worldwide , affecting 2% to  27% of the population, with 
most estimates varying from 12% to 20% (Bouras and Tangalos, 2009 ). The prevalence of 
constipation increases to 30% -40% among people aged >[ADDRESS_334345] pat ients, the 
condition is chronic  requiring life -long treatment  (Bouras and Tangalos, 2009 ).   
Constipation is much more common among patients with Parkinson’s disease  than in the 
general population . There are 1M people suffering from Parkinson’s disease  in the US , of which 
roughly 60%, or 600,[ADDRESS_334346] therapy  (Ondo et al., 2012 ; Zangaglia et al., 2007 ). This 
represents  an economic burden to the individual with Parkinson’s disease and to the healthcare 
system . According to the most recent Federal Supply Schedule (FSS; April 2016), the average 30 -
day reimbursed price for a basket of orally administered drugs for constipation  is approximately 
$260 or $3120 per year . This represent s about $1. 8B of prescription laxatives just for patients with 
Parkinson’s disease .  
Constipation not only constitutes a major economic burden but it also significantly affects 
the quality of life  of the individual with Parkinson’s disease , contributing to social isolation and 
depression.  Furthermore, t he severity of the symptoms correlates negatively with patient reported 
quality of life.   
An effective pro -kinetic medication  for individuals  with Parkinson’s disease  would be a 
useful addition to the currently avail able treatments for this disabling condition.  
1.1 Background  
Constipation is common in Parkinson’s disease  and often becomes symptomatic years 
before the onset of the motor dysfunction and the subsequent diagnosis of Parkinson’s disease  (Lin 
et al., 2014 ; Savica et al., 2009 ). There is substantial evidence that the neurodegenerative process 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  11 
 associated with Parkinson’s disease , namely the accumulation of toxic aggregates of  alpha -
synuclein, occurs within the enteric nervous system years before they appear within the brain  
(Braak et al., 2006 ). It is believed that the enteric nervous system ( ENS ), with its vast surface area, 
is subject to continuous insults from infectious agents and toxic substances. Although the function 
of alpha - synuclein is not known, inflammation within the nervous system leads to an increase in 
its intracellular levels  (Allen Reish and Standaert, 2015 ).   In individuals with Parkinson’s disease  
the increase in alpha - synuclein leads to the formation of neurotoxic aggregates, perhaps because 
of a failure  by [CONTACT_273727] (due to genetic factors) to effectively dispose of them  (Sahay et al., 
2016 ).  The aggregates of alpha - synuclein then traffic along the vagal nerve to the dorsal motor 
nucleus within the brainstem, and from there to more rostral structures  (Greene, 2014 ).  
The ind ividual with Parkinson’s disease  suffers from a form of constipation that is believed 
to be caused principally by [CONTACT_273728]. In addition, defecation is often 
impaired by [CONTACT_273729]’s disease patient’s anorectal ref lex. For many individuals 
bowel issues represent a significant detriment to quality of life. Failure to effectively manage this 
problem can also lead to bowel obstruction, especially as the terminal phase of Parkinson’s  disease  
approaches. A limited number  of therapi[INVESTIGATOR_273702], either by [CONTACT_273730] (Ondo et al., 2012 ; Zangaglia et al., 2007 ). 
Squalamine  is a small molecule, originally discovered in the liver of the dogfish shark, 
where it is delivered following a meal via the biliary tract into the intestine  (Moore et al., 1993 ). 
When squalamine  is applied to the isolated colon and/or jejunum of a mouse, the compound 
stimulates organized peristaltic waves  (Kunze et al, manuscript in preparation) . This effec t occurs 
throug h direct stimulation by [CONTACT_273731] (IPANS) which 
are the most abundant type of neuron within the ENS. The IPANs, in turn, excite the ganglia of 
the myenteric plexus, and promote propulsive peristalsi s. In addition, intense electrical signals are 
directed to the brainstem via the vagus following exposure of the ENS to squalamine  which persist 
for some time. Of relevance to this clinical study, squalamine  reverses the impaired motility of the 
colon from  aged animals engineered to express a Parkinson’s disease  phenotype.   
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  12 
 Furtherm ore, in a recent study, squalamine  has been shown to prevent the formation of 
toxic alpha -synuclein aggregates  ((Perni et al., 2017 )). The molecule accomplishes this as a 
consequence of its mechanism of action and the mechanism by [CONTACT_162826] -synuclein a ggregates 
to form toxic polymers. Squalamine enters a neuron and binds to the negatively charged 
phospholipi[INVESTIGATOR_273703]’s plasma membrane, 
effectively neutralizing the negative charge of the membrane surface. A lpha-synuclein normally 
binds to the cytoplasmic face of the membrane via the positive charge on its N -terminus. Thus, 
when squal amine  binds to the cytoplasmic face of the plasma membrane it displaces alpha -
synuclein into the cytoplasm. As the concentratio n of alpha -synuclein on the membrane decreases, 
the likelihood that monomers will aggregate into higher order polymers decreases, thus reducing 
the rate of formation of aggregates and thereby [CONTACT_273732]. At the same 
time, squalamin e excites the neuron by [CONTACT_273733].  Thus, squalamine  both excites the neurons of the ENS and protects them from alpha -
synuclein induced cytotoxicity. It is for these reason s that we will evaluate squ alamine  as a 
therapeutic to treat the constipation associated with PD  and why we will explore its effect on sleep 
architecture . 
1.2 Rationale for the Study  
Constipation is a major clinical component of Parkinson’s disease  and is reported to occur 
in greater than 60%  of affected individuals. The pathophysiological basis of constipation in 
Parkinson’s disease  is generally believed to be due to delayed transit through the colon  (Edwards 
et al., 1991 ; Klingelhoefer and Reichmann, 2015 ). Several studies have demonstrated tha t transit 
of stool through the colon of an individual with Parkinson’s disease  is about 50% that measured 
in age matched controls. As a consequence both stool frequency and stool consistency are 
abnormal in Parkinson’s disease . For many patients, as well a s those caring for these individuals, 
constipation remains a significant morbidity associated with the condition  (Salat -Foix and 
Suchowersky, 2012 ; Sung et al., 2014 ).  
 Few placebo controlled clinical trials have been conducted in the Parkinson’s disease  
population to assess the efficacy of therapeutics that could be of value. Addition of fiber to the 
diet, although increasing stool volume, is reported to have no effe ct on colon transit time (Ondo et 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  13 
 al., 2012 ; Zangaglia et al., 2007 ). An osmotic laxative, polyethylene glycol (M agrogol) has been 
studied in a  small placebo controlled clinical trial of individuals with mild constipation, and shown 
to provide benefit with respect to stool frequency and consistency  (Zangaglia et al., 2007 ). A short 
term placebo  controlled trial of Lubiprostone, a chloride channel activator which increases 
intestinal fluid secretion, was only effective in about 50% of those treated , and resulted in passage 
of loose stools/diarrhea in place of constipation  (Ondo et al., 2012 ). Furthermore, Lubiprostone 
delays gastri c emptying  (Camilleri et a l., 2006 ), a function already compromised in Parkinson’s 
disease .   
The pathophysiology of the GI dysfunction in Parkinson’s disease  involves deposition of 
alpha -synuclein within both the ENS as well as within the brainstem.  For reasons that remain 
unknown alpha -synuclein, which is a protein normally produced in neurons, forms neurotoxic 
intracellular aggregates in Parkinson’s disease . Numerous studies suggest that the alpha - synuclein 
aggregate formation begins in the ENS of the   Parkinson’s disease  individual many years before 
the onset of the motor symptoms (Braak et al., 2006 ).  As a consequence of the normal retrograde 
neuronal trafficking that occurs within the vagus nerve, toxic aggregates are transported from the 
neurons of the ENS to the dorsal motor n ucleus of the vagus, and then, gradually to sites within 
the  brain that  are involved in  physical movement and balance (Greene, 2014 ; Visanji et al., 2014 ). 
Because the constipation is fundamentally of an acquired neurodegenerat ive nature, it differs, so 
far as we now understand, from other forms of this condition  (Visanji et al., 2014 ). 
The mechanism of action of squalamine  has been elucidated over the past decade. The 
molecule is structural related to a bile salt, but bears a polyam ine, giving it a net positive charge. 
It is produced naturally in the liver of the dogfish shark and delivered along with bile salts to small 
intestine via the bile duct. Based on studies conducted ex vivo with isolated segments of mouse 
jejunum and colon,  and our knowledge of  squalamine ’s mechanism  of action at a cellular level,  
we can understand the prokinetic effects of squalamine  on intestinal motility.  Once within the 
lumen of the intestine squalamine  is transported from the epi[INVESTIGATOR_273704], including the intrinsic primary afferent neurons, the most abundant 
neuron of the ENS (Furness et al., 1999 ). Once within the neuron, the positively charged 
squalamine  molecule is attracted to the inner face of the plasma membrane, which has a negative 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  14 
 surface charge, due to the presence of anionic phospholipi[INVESTIGATOR_805], neutralizing the negative charge  
(Zasloff et al., 2011 ).  As a consequence, many proteins that are bound to the inner face of the 
cytoplasmic face of the plasma membrane are displaced or functionally altered, including ion 
channels and transporters  (Sumioka et al., 2009 ; Yeung et al., 2008 ). By [CONTACT_7652], 
squalamine  activates the firing of the IPANs, which in turn, activate the myenteric plexus, resulting 
in propulsive migrating motor complexes (MMCs ), and direct electrical activity rostrally to the 
brainstem via the vagus  (Kunze et al, manuscript in preparation) .  
Alpha -synuclein normally binds to membranes composed of a high proportion of anionic 
phospholipi[INVESTIGATOR_273705] N -terminus  (Shi et al., 2015 ). When the intracellular 
concentration of alpha -synuclein increases , the concentration of alpha -synuclein molecules bound 
to the inner face of the cytoplasmic membrane increases proportionally, and as it does the 
probability that they will physically contact [CONTACT_273734]. In individuals 
with Parkins on’s disease  these aggregates grow in size and eventually overwhelm the cell’s 
capacity to digest the inclusions, whereas in those without Parkinson’s disease  these aggregates 
are cleared by [CONTACT_273735]  (Recchia et al., 2004 ).  In a recent study we show that squalamine  
effectively displaces alpha -synuclein from the surface of a negatively charged membrane surface, 
and completel y prevents aggregate formation. These studies have been conducted in specialized 
in vitro systems as well as in a validated in vivo model of Parkinson’s disease , a genetically 
engineered strain of C. elegans expressing human alpha -synuclein. Oral treatment  of C. elegans 
with squalamine  prevents the aggregation of alpha -synuclein within the muscles of the animal and 
reverses the paralysis caused by [CONTACT_273736]  (Perni et al., 2017 ). 
Thus, squalamine  has the remarkable property of stimulating peristaltic activity by [CONTACT_273737], inhibiting the formation of 
neurotoxic alpha -synuclein aggregates within the same neurons. In principle, squalamine  could 
reverse the neurodegenerative process within the ENS of the individual with Parkinson’s disease . 
If indeed the pathophysiology of the CNS component of Parkinson’s disease  occurs as a 
consequence of the trafficking of alpha -synuclein aggregates from th e ENS to the brain via the 
connecting nerves, then squalamine  could have an impact on the disease process occurring within 
the CNS both therapeutically and prophylactically.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334347] 60 minutes after study medication.    The 
compound is highly charged and will adsorb to foodstuffs, so it is being administered prior to 
feeding.  
The dose rationale for this study was based on the extensive clinical experience gathered 
in the setting of clinical trials involving systemic administration of squalamine, experience 
gathered from its consumption in nutraceutical products, and pre -clinical pharmacology studies.   
  ENT -01, the phosphate salt of squalamine , is weakly soluble in  water at neutral pH but 
readily dissolves at pH< 3.5 (the pH of gastric fluid) .  Squalamine, as the highly water soluble 
dilactate salt has been extensively studied in over  3 Phase 1 and 8 Phase 2 human clinical trials as 
an intravenous agent for the tre atment of cancer and diabetic retinopathy  (Bhargava et al., 2001 ; 
Connolly et al., 2006 ; Hao et al., 2003 ; Herbst et al., 2003 ). The compound is well tolerated in 
single and repeat intravenous administration, alone or in  combination w ith other agents,  to doses 
of at least 300mg/m2). In the current clinical trial, ENT -01 will be administered orally to subjects 
with Parkinson’s disease who have long standing constipation. Although this trial will be the first 
in man oral dosing study of ENT -01, humans have long been exposed to low doses of squalamine  
(milligram to microgram) in the various commercial dogfish shark liver extracts available as 
nutraceuticals  (e.g., Squalamax) . In addition, following systemic administration squalamine is 
cleared by [CONTACT_273738] (in mice) into the duodenum through the 
biliary tract. Drug related GI toxicology has not been reported in published clinical trials involving 
systemic administration of squalamine. ENT -01 has limited b ioavailability in rats and dogs. Based 
on measurement of portal blood concentrations following oral dosing  of radioactive ENT -01 to 
rat’s absorption of ENT -[ADDRESS_334348]. However, ENT -01 appears to be well tolerated in 
both rats and dogs.   
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334349], safety margins 
based on mg/kg/day of ENT -01 are considered an appropriate safety met ric based on allometric 
comparisons of gastrointestinal dimensions between species (Kararli, 1995 ; Sharma and McNeill, 
2009 ).  
The proposed starting dose in the Stage 1 segment of the planned trial is 25 mg (0.33 mg/kg 
for a [ADDRESS_334350]). The NOAEL of a single oral dose in the rat is ≥ 1000 mg/kg, and in t he dog, 
≥200 mg/kg representing a relative safety margin for the proposed starting dose of about 3000x 
based on the rat and about 600x based on the dog. The proposed maximum single dose in Stage 1 
is 200 mg (2.7 mg/kg for a [ADDRESS_334351]) is covered by a s afety margin of about 300x based on 
the rat, and about 70x based on the dog.  
The maximum proposed dose to be evaluated in Stage 2 of the planned trial is 175 
mg/kg/day (2.3 mg/kg/day for a [ADDRESS_334352]), and the total daily dosing exposure will last no 
longer than 25 days. The NOAEL of 25 daily dosing in the rat is ≥ 80 mg/kg/day and in the dog, 
≥ 20 mg/kg/day, representing a relative safety margin for the proposed maximum daily dose of at 
least 35x based on the rat, and at least 9x based on the dog.  
No ga strointestinal lesions, either macroscopic or microscopic, were associated with oral 
dosing of ENT -01 any of the non -clinical studies conducted . Systemic blood levels of ENT -01 will 
be determined in this clinical trial. The chemical structure of squalamine  (highly wa ter soluble, 
amphipathic cationic zwitterion  of molecular weight 628) predicts poor oral bioavailability. 
Squalamine is well tolerated when administered by [CONTACT_273739] 200 -300 
mg/m2 over days to months of 5 day continuous infusions.  At these dosing rates steady state 
plasma concentrations range between 5 -10 µg/ml. Reversible elevation of hepatic enzymes is the 
major dose limiting toxicity, observed at dose rates above 300 mg/ m2, which is understood since 
squalamine is cle ared by [CONTACT_4852].  
The daily dosing range in the planned clinical trial is from 25 mg (14.7 mg/m2) to 200 mg 
(114 mg/m2). Oral dosing of ENT -01, because of its low oral bioavailability, is not anticipated to 
reach significant plasma concentrations in huma n subjects, based on nonclinical studies. Based on 
an oral bioavailability of 0.1%  observed in both dogs and rats  and the PK data from prior Phase 1 
studies of IV administration,  (where an IV dose of 12 mg/m2 yielded a C max of 0.8 µg/ml, and 90 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  17 
 mg/m2, a C max of 2 µg/ml)   the maximum plasma concentrations in man following a 25mg oral 
dose would be on the order of about 0.5ng/ml, and following a 200mg oral dose, about 2ng/ml.   
 The principal uncertainty related to potential toxicology on oral dosing in hum ans is the 
local effect of ENT -[ADDRESS_334353] of  colonic motility.  
From preclinical electrophysiological and motility studies conducted in the ex vivo  mouse 
jejunum and colon, squalamine concentrations  of between 30 -100M were required to stimulate 
the ENS and drive peristaltic contractions ( Kunze et al, manuscript in preparation ).  Based on the 
known fluid volume of the fasting stomach in normal subjects after ingesting an 8 oz. glass of 
water (about 2 40 ml)  (Mudie et al., 2014 ), a 100 mg dose of Enterin would achiev e  a concentration 
of about   500 M  in the stomach and would undergo progressive dilution as the bolus advanced  
rectally.  If we assume that 100mg (about 60 mg/m2) of ENT -01 is a prokinetic dose in Parkinson’s 
disease  patients, that the bioavailability o f squalamine (the active moiety) is no greater than  1% 
then blood levels would correspond roughly to no greater than that observed after a 0.6 mg/m2 i.v. 
dose (Bhargava et al., 2001 ; Hao et al., 2003 ; Herbst et al., 2003 ), which is at least 4 00-fold below 
the maximum tole rated  intravenous dose of about 300mg/  m2. 
We will monitor for potential systemic adverse events after oral dosing of ENT -01, with 
our principal focus on the local effects of the compound in the GI tract.  
 
 
2 OBJECTIVES  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  18 
 The purpose of this study is to evaluate the safety, tolerability , pharmacokinetics and 
pharmacodynamics  of orally administered ENT -01 at doses ranging from 25mg to 200m g in 
patients with constipation secondary to  Parkinson’s disease . Dosing will be  individually titrated to 
tolerability and effect .  A second  objective of the study is to determine the effect of orally 
administered ENT -[ADDRESS_334354] information relating to sleep and other non -motor symptoms of PD.  
2.1 Stage  1 
Primary objective:  
The primary objective of the Stage  1 study is to determine the safety and tolerability of a 
single oral dose of ENT -01 in patients with PD and constipation. The dose will be titrated to 
tolerability, starting at 25mg daily and increasing up to 200mg daily.  
10 patients will be enrolled in  the study for 7 -12 weeks.  
Safety end -point will be:  
Adverse events as measured by [CONTACT_52168], vital signs, clinical chemistry, and EKG  
Tolerability end -points  (referred to as the dose -limiting tolerability (DLT)) :  
• Recurrent vomiting  defined as 3-5 epi[INVESTIGATOR_273706] 24 hours of taking drug 
• Recurrent diarrhea  defined as 4-6 epi[INVESTIGATOR_273707] 24 hours of taking  drug 
• Abdominal pain  defined as moderate pain that limits instrumental activities of daily living 
(ADL) (e.g., preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, 
managing money, etc .) within 24 hours of taking drug  
• Postural hypotension defined as dizziness /lightheadedness  or fainting  on rising from lying 
to sitting  or standing  that limits instrumental  ADL  and severe enough to indicate  non-
urgent medical intervention within 24 hours of taking drug . 
• A fall in systolic blood pressure to <80mm Hg upon rising from lying to sitting or standing  
• A fall in diastolic blood pressure to <40mm Hg upon rising from lyin g to sitting or standing  
• Elevation of LF Ts > 3 times the upper limit of normal (ULN)  
• A reduction of body weight of 10% or more  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  19 
 Secondary objective:  
The secondary objective of the Stage  1 study is to evaluate the Pharmacokinetic (PK) 
characteristics of a single oral dose of ENT -01 in patients with PD and constipation.   
Pharmacokinetics:   
Animal studies have shown < 1%  ENT -01 absorption following oral administration . 
Plasma samples will be obtained for pharmacokinetics before dose administration and at 1, 2,  4, 
8, and 24 hours after dose administration on day 1 of each dose level. A PK analysis will be 
conducted if plasma concentrations exceed the lower limit of quant itation of 5 ng/ml  using a 
validated analytical method  (Li et al., 2004 ). The PK analysis of ENT -01 will be conducted by 
[CONTACT_273740] -independent methods as implemented in WinNonlin™.  The PK variables analyzed 
will include AUC 0-24 (ss), Cmax (ss) , Cmin (ss) , Tmax (ss) , CL/F , and  z,.  
The PK variables are summarized as follows:  
Cmax (ss)  Maximum or peak measured plasma concentration  
Cmin (ss)  Minimum or trough measured plasma concentration  
Tmax (ss)  Time of maximum or peak measured plasma concentration  
t½z Apparent terminal elimination half -life; calculated as ln(2)/ z.  The 
number of data points included in the regression will be determined by 
[CONTACT_31519], but a minimum of three data points in the terminal phase, 
excluding C max, will be required to estimate z. 
AUC 0-24 (ss) Area under the concentrati on versus time curve over the 16 -hour dosing 
interval; calculated using line ar trapezoid rule  
CL/F  Clearance defined as: Dose/AUC 0-24 (ss). 
 
2.2 Stage  2 
Primary objective s:  
The primary objective of the Stage  2 study is to determine the safety, tolerability , 
pharmacokinetic  and p harmacodynamic characteristics of repeated oral doses of ENT -01 in 
patients with Parkinson’s disease  and constipation.  
Animal studies have shown that orally administered ENT -[ADDRESS_334355] of orally 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  20 
 administered ENT -01 on bowel function in patients with PD and constipation will be determined 
clinically using stool frequency, consistency and ease of passage. Constipation will be defined 
according to history and Rome -IV criteria  at baseline  (See Inclusion Criteria ). During the study, 
all participants will maintain a daily diary of stool frequency, consistency and ease of passage. 
Date and dose of study medication and of bowel movement, stool consistency according to the 
modified Bristol scale and ease of passage of e ach stool on a 7 -point adjectival scale as well as use 
of manual aids and suppositories will be recorded.   
Exploratory Objectives:  
The first exploratory  objective of the Stage [ADDRESS_334356] of orally 
administered ENT -01 on slee p, temperature , memory, energy  and mood  in patients with 
Parkinson’s disease. During the study, all patients will maintain a daily sleep diary. The y will 
record bed time, sleep time and morning waking, hours slept each night, number and duration of 
wakes, and leg twitching/thrashing during the night. In addition, we will evaluate sleep indirectly 
using  an I-Button  which  measure s skin temperature. Diu rnal variations in temperature correlate 
well with the sleep -wake cycle  (Sarabia et al., 2008 ; van Marken Lichtenbelt et al., 2006 ). The 
patients will be asked to wear the I-Button  attached to a wrist -band for five consecutive 24 hour 
periods during the basel ine period (Period 3.1), during the stable -dose period (Period 3 .2), the 
randomized period (Period 4)  and part of the wash -out period . They will remove it only during 
showering.  Mood , fatigue, hallucinations, memory and executive function  will all be assessed at 
baseline, during  the fixed do se period and at the end of the randomization period using the B eck 
Depression Index (B DI), REM behavior disorder questionnaire (RBDQ), Parkinson Fatigue Scale 
(PFS -16), University Miami Parkinson Disease Halluci nation Questionnaire  (UM -PDHQ), NMS 
questionnaire (NMS) , MMSE and Trail -making A and B) , respectively .    
Primary Efficacy End -point:   
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  21 
 The primary efficacy end -point will be regularization  of bowel function as determined by 
[CONTACT_273741].  This will be de fined as an increase in frequency by [CONTACT_273742], 
complete bowel movement per week compared to baseline  or three or more spontaneous, complete 
bowel movements per week . Assessment will occur at the end of the fixed -dose period (Period 
3.2) and baseline will be obtained at the end of the run -in period (Period 3.1) and all patients (n= 40) 
will be compared with their baseline bowel function . During the randomized period (Period 4) the 
treatment group will be compared to the placebo group usin g the same criteria  (n=20 in each 
group) . 
Summary of success criteria : (at least one of the following is met)  
• Complete spontaneous stool frequency increase by 1 or more over baseline or  
• Spontaneous, complete stool frequency of three or more per week  
Explor atory  End-point s:  
The exploratory  end-point s include  increase in colonic motility during the randomized 
period  over baseline values  and comparison of motility between treatment and control groups 
during the randomized period . Colonic motility will be measured by [CONTACT_273743] 
(MCT) time based on a single film estimate (Metcalf et al., 1987).  
Other Exploratory End -points:  
Sleep diaries will provide subjective assessment of sleep parameters. BDI will provide 
subjective assessment of mood. PFS-16, NMSQ and UM -PDHQ will provide subjective 
assessments of fatigue and hallucinations.  Non-motor symptoms (NMS) questionnaire  will 
provide subjective assessment of overall NMS burden  and will be supplemented with the RBD 
and PDSS questionnaires . PAC -SYM and PAC -QOL will provide subjective assessment of bowel 
function and QOL issues. MMSE and Trail -making A and B will provide objective assessment of 
memory and executive function.  The I-Button  will provide objective assessments of skin 
temperature diurnal v ariations and will be a surrogate assessm ent of delays in sleep onset,  awake 
periods  and Circadian rhythm .  
• Sleep diary  
• I-Button  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  22 
 • BDI 
• MMSE  
• Trail -making A and B  
• UM-PDHQ  
• PFS-16 
• NMSQ  
• RBDQ  
• PDSS  
• PAC -QOL  
• PAC -SYM  
[ADDRESS_334357] of 7 periods. Total duration will be 21-29 weeks  (maximum 
treatment period  for each individual is  4-8 weeks) . 
 
 
  
Period 1 Period 2.1 Period 2.2 Period 3.1 Period 3.2 Period 4 Period 5
Run-in 
sentinel 
group 
(Cohort 1)Single 
dose 
escalation 
sentinel 
group  Washout Run-in 
(Cohort 2)Identification 
of prokinetic 
dose  using a 
[ADDRESS_334358] 
sentinel group 
followed by 
[CONTACT_273744]1:1 
Randomization 
onto placebo 
or prokinetic 
doseWashout 
2 weeks 3 weeks 2 weeks 2 weeks 3-5 weeks 2 weeks 2 weeks
N=10 N=10 N=10 N=40 N=40 N=40 N=40STAGE 1 STAGE 2A≤17days  6 days  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  23 
 3.1 Periods  
PERIOD  1 (Stage  1):  
Run-in period for Sentinel Group (n=10 ) 
Duration: 2 weeks  
Conducted at home with 1visit to the clinical trial facility  and a telephone call at day 14  
 Patients who meet the inclusion /exclusion  criteria and who sign an informed consent will 
be enrolled in the study. The sequence of patients entering the study will be used to generate the 
patient iden tifying number for the  conduct of the study  (e.g., all case report forms, laboratory 
assessments ). At the beginning of the run -in period, patients  will be asked to stop benzodiazepi[INVESTIGATOR_273708], hypnotics, opi[INVESTIGATOR_858] , proton pump inhibitors . Patien ts will remain off these 
medications throughout the study.  They will be allowed to continue antihistamines, anti -
cholinergics, anti-psychotics, dopamine , and anti -depressant medication  at stable doses . Use of 
laxatives and suppositories  will be documented  in the stool diary. Laxatives, softeners, Dulcolax 
suppositories and enemas will be disallowed during the [ADDRESS_334359] various sleep parameters.  At the end of the  Period, t hey will  be re -evaluated  using 
the daily stool chart  to assess the severity of constipation . A stool occurring within 24 hours of 
laxativ e, stool softener, bulking agent  or suppository use will not be counted.  Only spontaneous 
stools will be counted. A spontaneous stool is a stool occurring in the absence of a laxative , stool 
softener, bulking age nt or suppository.  
Exploratory Sleep Assessment:   
Between the 9th and 14 th days (range 8-15 days) , patients will wear an  I-Button  
continuously except during periods of bathing  (See Appendix) . Measureme nt of extremity 
temperature has been  validated against polysomnography as a surrogate for  measuring sleep onset 
and fragmentation . Other baseline testing during this period will include NMS Q, PFS-16, BDI, 
UM-PDHQ , RBDQ, PDSS, MMSE, and Trail -making A and B , PAQ -SYM and PAC -QOL . 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  24 
 Symptoms of Parkinson’s disease will be assessed using the Unified Parkinson's Disease Rating 
Scale (UPDRS) during ON states. ON -state will be reached one hour after dopamine intake.  
Visit Day 1 : Informed Consent  
The eligible subjects will be asked to sign the inf ormed consent after the study has been 
explained to them and after all their questions have  been answered.  
At the beginning of the run -in period, the sentinel group of [ADDRESS_334360] screening 
visits. In the screening visit inclusion and exclusion c riteria will be accurately reviewed  and 
constipation history asses sed by [CONTACT_273745], consistency, ease of 
evacuation, duration of constipation, use of laxatives , stool softeners, bulking agents  and also  
using the Rome I V criter ia; Patients with a history of constipation of longer than [ADDRESS_334361] to enter in the study and within 48 
hours of each of the studies. They will also be instructed as to the use of daily diaries and I-Button s 
and told to use them during a five-day period during the second week  as described above  and 
continue for the remainder of the study . The stool chart will contain daily information relating to 
bowel movement, stoo l consistency, ease of passage  and use of laxatives , softeners, bulking agents  
and suppositories.   
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  25 
 Phone call  Day 14:  
Assessment of constipation severity off medication  
Participants  will receive a phone call and be asked about adverse events. They will also  
provide their daily stool chart  to assess the severity of the constipation and use of laxatives , 
softeners, bulking agents  and suppositories . Patients with two or fewer complete, spontaneous 
bowel movements will qualify for the treatment period. A bowel movement occurring within 24 
hour s of suppository , softener, bulking agent  or enema use will NOT be counted. A spontaneous 
stool is a stool occurring in the absence of a laxative , softener, bulking agent or suppository.  
PAC -SYM and PAC -QOL to be administrated on day 14, or at the clinic a t Dose 1 visit the 
following day if they fail to bring the completed survey.  
PERIOD  2.1 (Stage  1):  Single dose  
Safety,  tolerability  and pharmacokinetics  of orally administered single -dose ENT -01 in 
Sentinel Group  
Duration: [ADDRESS_334362] two patients  (subjects 1 -2) will 
first be admitted and given a single dose. The study will be conducted at a hospi[INVESTIGATOR_307] -based clinical 
unit and patients will be monitored fo r 24 hours after the dose. Unless there are any safety 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  26 
 concerns, patients will be released at this time and brou ght back for the next dosing  on Day 4 -8 
(D4-8), after a minimum of a [ADDRESS_334363] elapsed and provided there 
are n o safety concerns, they wi ll all be sent home and instructed to return on Day 7  for the next 
dosing level.  This single dosing regimen will be continued until each patient has been given a 
single dose of 200mg  or has reached a dose limiting toxicity (D LT). DLT will be the dose  which 
induces  repeated vomiting , diarrhea , abdominal pain or symptomatic postural hypotension within  
24 hours  of dosing . Maximum tolerated dose (MTD) will be the highest dose for which there 
was no more than 1 DLT  endpoint (refer to Section 9.8, DLT endpoint criteria ). A review of 
safety,  tolerability  and adverse events  will occur prior to administration of each dose le vel and at 
the end of  Period  [ADDRESS_334364] dose of medication, BDI, MMSE, Trail -making A 
and B, NMS Q, UM-PDHQ , PFS-16, RBDQ, PDSS, PAC -SYM and PAC -QOL  will be 
administered . 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  27 
 Schematic for Stage 1, Period 2.1:  Hypothetical dosing regimens  
 
 
 Pharmacokinetics:  Timed blood samples (5.0 mL) will be collected into Li-Heparin 
treated tubes for analysis of ENT -01 plasma concentrations. Plasma samples will be obtained for 
pharmacokinetics before  dose administration and at 1, 2, 4, 8, and 24 hours.  
 Once collected, PK samples will be stored in a -20ºC or -70ºC freezer until time of 
shipment.  Labels and appropriate shippi[INVESTIGATOR_273709]. The concentration 
of study drug will be determined from the plasma samples using a validated  analytical method.  
Details of the method validation and sample analysis will be included with the final clinical study 
report.  
Individual stoppi[INVESTIGATOR_3418]:  
The complete panel of Blood Chemistries described in Appendix [ADDRESS_334365] 1 DLT endpoint  (see Section 9.8), or with an other non -DLT  
gastrointestinal AE >  grade [ADDRESS_334366] , 
ALT , or total bilirubin > 3x  ULN  or a reduction of body weight of 10% or more from baseline  will 
be terminated .  ENT -01 has very little systemic absorption, and hence adverse events are expected 
to be within the gastrointestinal  system .    
MTD:  Maximum Tolerated Dose
ID: Intolerant Dose
prokinetic response MTD ID
Subject Day [ADDRESS_334367] someNo 
response
 Stage 1     
Period 2.1  
(COHORT 1)      
Single dose 
safety, 
tolerability and 
identification of 
prokinetic dose 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  28 
 Refer to Section 9.12 for Adverse Event Grading  and to Section  9.8 for DLT Endpoint 
Criteria.  
Go/No -go decision:  
Safety:  We are assuming that no more  than 1 patient out of ten ( 10%) will have an adverse event 
of grade [ADDRESS_334368] possibly 
related to ENT-01 for doses less than 200 mg , the study will be put on an immediate safety hold 
until an emergency DSMB meeting can be held to evaluate the study for possible discontinu ation . 
Dose -finding:  Beyond the safety and t olerability, this Period will allow us to determine the dose 
whic h is safe and tolerable in all 10  patients  (STD)  and which has a pro -kinetic eff ect in at least 
some patients (S TDE: Safe and Tolerable dose in all and pro -kinetic Effect in at least some). W e 
will start Period 3 with the STDE.  
PERIOD 2.2  (Stage  1):  Washout  
Duration: 2 weeks  
Patients will be  observed  off study drug  and adverse events will be recorded . They will 
continue to keep a daily diary throughout the period. They will  continue to wear the I-Button  for 
five 24 h our periods between Days 1 and 5. During the second week, they will be restarted on all 
original medications but will continue their diaries until the termination of the study. They will be 
seen prior to study termination  and BDI, MMSE, Trail making A and B, NMS Q, UM-PDHQ , PFS-
16, RBDQ, PDSS, PAQ -SYM and PAC -QOL  will be administered . 
Visit 2:  Day 14  
Patients will be reviewed prior to discharge and any adverse events noted.  
DSMB review of Stage 1: The DSMB will determine whether to proceed to Stage 2.  
PERIOD 3.1 ( Stage  2a)  
 Run-in period for Cohort 2  (n=40) 
Duration: 2 weeks  
Conducted at home.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  29 
 Forty patients will be screened and included in the study on the assumption that roughly 
15% will drop -out, leaving [ADDRESS_334369] stool 
frequency, consistency, ease of evacuation, completeness and use of suppositories (if it occurs)  
and various sleep parameters. The diaries will be reviewed daily by [CONTACT_273746].  Patients with two or fewer complete, SPONTANEOUS bowel movements will have 
the Sitzmarks motility assessment, complete the run -in period and proceed to the treatment 
period. Bowel movements occurring within 24 hours of a suppository, (or accidentally used 
laxative, bulking agent, softener) or enema will not be counted.  At the end of the first week, 
assuming they are allowed to proceed to the treatment period, they will also have Sitzmarks 
motility assessment to assess baseline colonic motility. Symptoms of Par kinson’s disease will be 
assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) during ON states. ON -state 
will be reached one hour after dopamine intake.  
 Sleep Assessment:  Patients will wear an I-Button  continuously from Day 8 of the R un-In 
Period to Day 5 of the W ash-Out period except during periods of bathing.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  30 
 Visit Day 1 : Informed Consent  
The eligible volunteers will be asked to sign the informed consent after explanations of the 
study and after all their questions have been answered.  Patients will be registered to the study after 
they have provided informed consent.  
At the beginning of the run -in period, the  new cohort of  [ADDRESS_334370] been filling in for a week will be reviewed and thos e 
patients with two or fewer complete, spontaneous bowel movements per week will proceed to 
Sitzmarks assessment. This will trigger shipment of study drug.  
Sitzmarks procedure  Days 8, 9, and 10: 
• The patient will self -administer the Sitzmarks capsule (contains 24 radiopaque markers; 
Konsyl Pharmaceuticals, [LOCATION_007], [LOCATION_003]) by [CONTACT_273747] 8,9 , and 10 and will 
consume their usual diet during this period . The patient will abstain from using suppositories 
or enemas until they return on Day 11. An abdominal XR will be scheduled on Day 11  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  31 
 Day 11 – Site Visit [ADDRESS_334371] 80% (19 or more o f the markers) have 
grossly normal colonic transit. If remaining markers are scattered about the colon, the condition is 
most likely hypomotility or colonic inertia. If remaining markers are accumulated in the rectum or 
rectosigmoid, the condition is most likely functional outlet delay. Radiographs will be collected in 
electronic format and subsequently analyzed in blinded manner by a centralized reader (Michael 
Camiller i MD, and Duane Burton, MHA, Division of Gastroenterology and Hepatology, Mayo 
Clinic). The patient will be given study medication  (B) and a PAC -SYM and PAC -QOL  to take 
home . This will trigger randomization to treatment or placebo and to PK or no PK . 
 
Day 14 - Phone call    
Patients will be asked to complete the PAC+SYM and PAC -QOL questionnair es. They  
will be instructed to take the medication  the following morning  on an empty  stomach  and not to 
eat anything for at least 60 minutes thereafter . Baseline complete, spontaneous bowel movements 
(CSBM) will be calculated from the diaries at the 14 day  phone call as CSBM/entries x 
7.Baseline PAC -SYM and PAC -QOL and baseline ease of passage and consistency will also be 
obtained at this time -point.  
PERIOD  3.2 (Stage 2 ): Multiple dose s 
Safety,  tolerability  and pro -kinetic effect  of orally administered multiple -dose ENT -01 in 
Sentinel Group followed by [CONTACT_273748] 2  (40 patients , of which 10 comprise the sentinel group ):  
Duration: 17-[ADDRESS_334372] two of the three dosing days.  Once the 
pro-kinetic dose is established, and assuming there are no safety concerns, each patient will be 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  32 
 kept on that fixed dose for a further 2-4 dosing days (3 days if it falls on a  Saturday, 4 days if it 
falls on a Sunday) . 
The sentinel g roup will be a group of  10 patients  who did not participate in Stage 1 . Patients  
will be given three consecutive doses of the dose which was found to be safe and tolerable in 
everybody (STDE) and effective in at least some patients in Stage 1 ( 75 mg in schematic ) at home. 
Patients will self -administer the study medication  daily  for 3 doses ( 3 days at each dosing level) . 
The dose will be taken  upon awakening  on an empty stomach  along with 8 oz. of water  
simultaneously to dopamine) . The patient will not be allowed to ingest any food for at least [ADDRESS_334373] two of the three days  at a given dose, then the patient will be told to proceed to the 
higher dose of STDE+25mg (eg.1 00mg qd) and also to use a suppository followed by [CONTACT_273749] (See rescue diagram below) . At the end of th e second 
dosing period  (100mg for 3 days) , the same criteria will be applied to make a determination as to 
wheth er to proceed to STDE+5 0mg (e.g. 125 mg qd) or not. The incremental dosing will continue 
up to the consistently clinically effective (pro -kinetic) dose , or to the DLT , whichever comes first. 
Patients who do not have pr o-kinetic effect at DLT  will be treated wi th the highest dose at which 
they did not have a DLT, if it is at least the STDE dose; if the DLT occurred at the STDE dose, 
then the patient will be terminated . Should a pro -kinetic response not occur at 175 mg, patients 
will take 175 mg for th e 2-4 addit ional  fixed -dose dosing days and 6 randomized dosing days 
(assuming  randomization is to treatment) . DLT  will be  the dose inducing repeated vomiting  or 
diarrhea  within [ADDRESS_334374] dose producing a CSBM  on 2/3 consecutive doses 
will be noted as the pro -kinetic dose (LSTDEi i.e. consistently clinically effective safe and 
tolerable dose for that particular individual).  Patients  will be kept on the lowest dose producing 
a pro -kinetic effect  for another 2-4 days prior to randomization  in Period 4 . The Enterin CMO  will 
review the stool diaries prior to randomization to ensure dosing adequacy.  PAC -QOL and PAC -
SYM will be repeated prior to randomization  at Visit 3 . CSBM during the fixed dose period will 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  33 
 be calcu lated as CSBM/#fixed dose days x 7. The primary end -point is obtained by [CONTACT_273750] -in period.  
2: SUPPOSITORY/ENEMA RESCUE USE DURING DOSE ESCALATION IN STAGE  
 
Figure [ADDRESS_334375] dose ( e.g. 75 mg) and will remove 
them on day 5 of the  wash -out period .  The remaining 3 0 patients will start on STDE ( e.g. 75mg) 
as soon as they have completed the Run -in Period  and will follow the same incremental dosing 
regimen until they reach their LSTDEi or maximum tolerated dose.  These regimens and 
adjustments are shown in the schematic below .  
Once the LSTDEi has been established, each patient will remain on that dose for two  to 
four additional  days prior to randomization in Period 4  (5 to 7 consecutive days on prokinetic 
dose)  
N.B. Primary end -point is obtained by [CONTACT_273751] e run -in period . 
Visit 3 for non -PK patients (Day before Randomization) .  
Non- PK patients will come to the site for a visit to return any unused study drug (B), receive 6 
daily doses of randomized drug (A or C), Sitzmarks capsules and will complete all th e 
questionnaires listed below. They will be sent home with 6 daily doses of A or C and Sitzmarks 
capsules and will return for Visit 4 on Day 6 of randomization to complete all the questionnaires.  
Go/No -go decision s:  
Safety:  We are assuming that no more th an 1 patient s out of forty  (2.5%) will have an adverse 
event of grade [ADDRESS_334376] possibly related to Enterin -0 in this cohort 
75 
 75 
 75 
 100 
 100 
 100 
 125 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  34 
 of 40 patients, the study will be  put on an immediate safety hold until an emergency DSMB meeting 
can be held to evaluate  the study  for possible discontinuation.  
Tolerability:  We are assuming t hat all patients will exhibit a pro -kinetic effect at a dose lower 
than DLT  and less than or equal to 175mg . Patients reaching DLT before a pro -kinetic effect will 
be terminated  if the highest dose for the patient without a DLT was the STDE dose . Otherwise  the 
patient will be treated at the highest dose at which they did not experience a DLT if they are 
randomized to the treatment arm (or will receive the equivalent dose of placebo).  
Efficacy: We are assuming that a consistent pro -kinetic effect will be obs erved in all patients. 
Patients in whom a pro -kinetic effect is not observed at the maximum dose of 175mg will cont inue 
to take 175mg for another 2  days and enter the randomized period . If they are randomized to 
treatment, they wi ll be given 175mg/day for the 6  randomized dosing days.   
Individual stoppi[INVESTIGATOR_3418]:  
Patients who reach DLT before a pro -kinetic effect, exhibit LFT e levation above 3xULN , 
have a 10% or greater reduction in body weight  or those with a non -DLT gastrointestinal AE >  
grade [ADDRESS_334377] possibly attributable to ENT -01 will be 
terminated.   
Pharmacodynamics: Patient will record bowel movements , ease of passage, consistency and 
suppository usage  in the daily diary throughout the  Period and transmit the information to the 
coordinator every evening.  
Sleep assessment:  Patients will wear the I-Button  throughout the dosing period  and remove it  
only during bathing periods . 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  35 
 Schematic of Stage 2, Period 3.2 with hypothetical dosing regimen  
 
DSMB: The DSMB will meet at the end of the fixed dose period for the ten sentinel patients .  
PERIOD 4  
(Stage  2): Randomized , double -blinded  treatment period  to determine the effect of orally 
administered ENT -01 on pharmacodynamics and motility.  
Duration:  6 days 
Visit 3  for PK patients (Day 1 of randomization):  
PK subjects will come to the site on Day [ADDRESS_334378] ionnaires completed.   
Followin g the  5-7 day course on the  pro-kinetic dose,  ALL patient s will be randomized to 
drug or placebo and enter Period 4. Randomization will be 1 :[ADDRESS_334379] Day1 Day2 Day3 Day4 Day5 Day6 Day7 Day8 Day9 Day10 Day11 Day 12 Day13 Day14 Day15 Day16 Day17 Day18 Day19 Day20 Day21 Day22
1 75 mg 75 mg 75 mg 100mg 100mg 100mg 100mg 100mg 100mg 100mg
2 75mg 75mg 75mg 100mg 100mg 100mg 100mg 100mg 100mg 100mg
3 75mg 75mg 75mg 100mg 100mg 100mg 125mg 125mg 125mg 125mg 125mg 125mg 125mg
4 75mg 75mg 75mg 100mg 100mg 100mg 125mg 125mg 125mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg
5 75mg 75mg 75mg 100mg 100mg 100mg 100mg 100mg 100mg 100mg
6 75mg 75mg 75mg 100mg 100mg 100mg 125mg 125mg 125mg 150 mg 150mg 150mg 150mg 150mg 150mg 150mg
7 75mg 75mg 75mg 75mg 75mg 75mg 75mg
8 75 mg 75 mg 75 mg 100mg 100mg 100mg 100mg 100mg 100mg 100mg
9 75mg 75mg 75mg 100mg 100mg 100mg 125mg 125mg 125mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg
1075mg 75mg 75mg 100mg 100mg 100mg 125mg 125mg 125mg 150mg 150mg 150mg 175mg 175mg 175mg 175mg 175mg 175mg 175mg
COHORT 2 
GROUP, N=32 RUN-IN PERIOD FOR SUBJECTS 11-40 Day7 Day21
Day 23 Day24 Day25 Day26 Day27 Day28 Day29 Day30 Day31 Day32 Day 33 Day34 Day35 Day36 Day37 Day38 Day39 Day40 Day41 Day42 Day43 Day44
COHORT 2 
GROUP, N=3211-[ADDRESS_334380] 2 of 3 
days at that doseLSTDEi
Stage 2,  
PERIOD 3.2, 
(COHORT 1)  
Safety and 
tolerability of 
3 day dosing, 
and extension 
to a total of 5 
doses  STDE 
DOSE
COHORT 1, 
SENTINEL 
GROUP  N=10
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  36 
 treatment and will remain blinded throughout the remainder of t he study.  BDI, MMSE, Trail 
making A and B, NMS Q, UM-PDHQ, PFS -16, RBDQ, PDSS, PAC -SYM and PAC -QOL will be 
administered prior to randomization .  The UPDRS will be administered and weight  and vital signs 
will be taken ). 
Assuming randomization is to treatment  group, the patient will remain on that dos e daily 
for a  6 day period  (6 dosing days) . Patients randomized  to placebo will be switched to  the same 
number of placebo tablets  as they were taking prior to switching.  All p atients will continue to keep 
daily diaries during this period. Th e use of rescue medication  (suppositories  and enemas ) for 
constipation  will be permitted as needed if a bowel movement has not occurred for [ADDRESS_334381]  day as shown in Figure 1 above . Any bowel movement produced as a result of rescue 
medication will not be counted.  
Patients reaching their tolerability limit at a dose lower than a clinically effective dose 
(STDE) will be terminated from the study. We have included 40 patients in this Stage  to allow for 
15% drop -outs for reasons including tolerability.  
Patients will wear the  I-Button  continuously throughout the randomized period except 
during bathing periods. Stool and sleep diaries will be completed daily throughout the period.  BDI, 
MMSE, Trail making A and B, NMS Q, UM-PDHQ , PFS-16, RBDQ, PDSS , PAC -SYM and PAC -
QOL will be administered on the first (Visit 3) and last day  (Visit 4). 
 
Pharma codynamics  WSW :  
On Day [ADDRESS_334382] a second set of motility tests 
(Sitzmarks capsules)  to determine whether there has been any improvement in colonic motility. 
Patients will be compared against their own baseline motility and the placeb o group will also be 
compared to the treatment group. The protocol will be identical to the baseline motility assessment. 
Patients will self -administer one capsule per day for three days beginning on Day 3 of the 
randomization period with subsequent capsul es taken on Day 4 and Day 5. An abdominal XR will 
be scheduled on Day 6.  Motility  at the end of the randomized period  will be compared with 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  37 
 baseline  for all 40 patients  and motility will also be compared between treatment and placebo 
groups  (20 patients per group) . 
Safety and tolerability will be reassessed throughout  the randomized treatment period . The 
study coordinator will call each patient at the end of each day  and patients will be told to call the 
coordinator whenever they need to.   
 
Summary of Stage  2, Period 4  
 
Pharmacokinetics and LFTs: On the randomization Day 1, [ADDRESS_334383] blood draw .  These same 10 
patients will undergo repeat blood draws for PK analysis and LFTs during their visit to the clinical 
trial unit on randomization Day 6 for the abdominal x -ray and repeated  patient 
questionnaires/surveys . Study medication  will be administered by [CONTACT_273752] [ADDRESS_334384] blood draw.  
PERIOD  5 (Stage  2): Wash -out period  
Duration: [ADDRESS_334385] 5 days of this period. During the las t visit, the UPDRS , BDI, Trail -Making A 
and B, MMSE, PFS-16, NMSQ, UM -PDHQ , RBDQ, PDSS, PAC -SYM and PAC -QOL  will be 
administered  
6 daily doses
LSTDEiRandomized 
1:1Stage 2  
PERIOD 4 
Double 
blinded, 
randomizedAll cohorts, 
N=40After 4th  
dose at the 
LSTDEiPLACEBO
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334386] PD and constipation as defined by [CONTACT_273753]. PD will be diagnosed according to the [LOCATION_006] Parkinson’s  Disease Society Brain 
Bank  criteria . 
4.1 Number of Patients  
Roughly 50 patients will be included. Ten patients will be included in Stage  1 and 40 
patients in Stage  2. Assuming a 15% drop -out rate, 8-9/10 patients will complete Stage  1 and 3 4/40 
patients will complete Stage  2. 
4.2 Selection Criteria  
Patients will be selected by [CONTACT_273754]. Patients will be screened for the presence of non -motor symptoms of P D, 
specifically constipation  and REM behavior disorder (RBD) . The population will be enriched 
with respect to NMS, specifically sleep delay and sleep fragmentation problems, and RBD . The 
presence of constipation at baseline will be established according to the Rome IV criteria and other 
inclusion criteria below . Onset of constipati on before or after a diagnosis of PD will specifically 
be noted and its duration and severity established. The daily stool diary will be analyzed  at the end 
of the two week run -in period to establish the presence of s evere  constipation on rescue medication  
alone (does not apply to Stage 1) . Patients with two or fewer complete, spontaneous bowel 
movements per week will be entered into the treatment phase. RBD  will be determined by [CONTACT_273755] . The use of anti -depressants , anti-cholinergics  and anti-psychotics  will be 
permitted as long as patients are on a stable dose of medication.  
4.3 Inclusion Criteria   
• Patients aged 30 -86 year old, both genders  
• Subjects must be diagnosed with Parkinson's disease (PD), according to the [LOCATION_006] 
Parkinson’s  Disease Socie ty Brain Bank  criteria , by a neurologist specializing in 
movement disorder s. 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  39 
 • There are insufficient criteria for IBS  
• Constipation which has been present for over [ADDRESS_334387] line, 
typi[INVESTIGATOR_273710] (1 gram) , Miralax (17g 
in 8 ounces of water)  or the equivalent  at least once weekly with an inconsistent 
response over a 6 week period . 
• Body mass index of 18 -40 kg/m2 
• Subjects must fulfill Rome I V criteria  for functional  constipation which includes 2 or 
more of the following:   
o Straining during at least 25% of defecations  
o Lumpy or hard stools in at least 25% of defecations  
o Sensation of incomplete evacuation for at least 25% of defecations  
o Sensation of anorectal obstruction /blockage for at least 25% of defecations  
o Manual maneuvers to facilitate at least 25% of defecations ( e.g., digital evacuation, 
support of the pelvic floor)  
• Fewer than 3 spontaneous, complete defecations a week.  
• Loose stools are rarely present without the use of laxatives  
• Patients must provide written informed consent and be willing and able to comply with 
study procedures.  
• Patients must be able to read, understand, and accurately record data into the diary to 
guarantee full participation in the study.  
• Fema le patients must have negative serum or urine pregnancy tests and must not be 
lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or 
injectable) and single -barrier method, or a double -barrier method of birth control must 
be u sed throughout the study. A vasectomized partner will be allowed as one in 
conjunction with another single -barrier method.  
• Female patients unable to bear children must have this documented in the case report 
form (i.e., tubal ligation, hysterectomy, or pos tmenopausal [defined as a minimum of 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334388] menstrual period]). Post -menopausal status will be confirmed 
by [CONTACT_9284] (FSH) in women less than 60 years of age  
4.4 Exclusion Criteria  
• Unable or unwilling to provide informed co nsent or to comply with study procedures.  
• Diagnosis of secondary constipation beyond that of PD  
• Structural or metabolic diseases that affect the GI system  
• Functional GI disorder  
• Unable to withdraw the following medications 2 weeks prior to the dose -escalation 
period and throughout the study: Laxatives, opi[INVESTIGATOR_858], sedatives, hypnotics, protein pump 
inhibitors or any medications which may cause constipation  
• History of recent major sur gery (within 60 days of screening)  
• Any clinically significant abnormalities on screening laboratories or physical 
examination  requiring further evaluation or treatment.  
• Neurological disorder other than PD  
• On treatment with intra -jejunal dopamine  or carbido pa/levodopa (i.e. Duopa)  
• Treatment with COMT inhibitors (entacapone, t olcapone, Stalevo ) 
• Patients starting a new PD medication or modifying an existing medication within 4 
weeks prior to enrollment  
• Unable to maintain a stable diet regimen  
• Patients with a cognitive impairment that preclude them from understanding the 
informed consent  
• Patients placed under legal guardianship  
• Acute GI illness within 2 weeks  of the baseline period  
• History of major GI surgery (e.g. previous abdominal surgery , including 
Cholecys tectomy ), except that patients with uncomplicated appendectomy are allowed.  
• ALT or AST > 1.5 X upper limit of normal (ULN) during screening  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  41 
 • Females who are pregnant or breastfeeding  
• History of excessive alcohol use or substance abuse  
• Patient or caregiver u nable to administer daily oral dosing.  
• Participation in an investigational clinical study within the 6 months prior to dosing in 
the present study.  
• Any other reason, which in the opi[INVESTIGATOR_273711] . 
4.5 Discontinuation  Criteria  
Patients may withdraw voluntarily from participation in the study at any time and for any 
reason. They may want to withdraw because of increased constipation off laxatives, nausea, 
vomiting or diarrhea.  
Patients may be wi thdrawn on the basis of the medical monitor safety and tolerability 
review or the Investigator’s clinical judgment, protocol deviation , change in dose of medications 
unrelated to study medication  or loss to follow -up. 
This study may be terminated at the di scretion of the Enterin, Inc. or of any regulatory 
agency for reasons including safety and/or efficacy.  
An Investigator may elect to discontinue or stop the study at his or her site for any reason 
including safety.  
When a patient withdraws or is withdrawn  before completing the study, the date and reason 
for withdrawal are to be documented in the eCRF.  The study site must immediately notify the 
medical monitor.  Patients who withdraw prematurely are to attend an early discontinuation visit 
if possible, at which time they will complete all assessments.  
In the event that a patient  is withdrawn prematurely due to an AE or serious AE, the AE or 
serious AE wil l be followed until it resolves  or stabilizes, or until it is judged by [CONTACT_273756].  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  42 
 4.6 Concomitant Medication  
• Preventive laxatives will be discontinued during the run -in period. Throughout the study, 
patients will be allowed to take constipation  rescue medication on demand , and only if 
they have not had a bowel movement in three consecutive days.  
• In stage 1 , rescue medication (laxative, bulking agent, softener, suppository)  can be taken 
as needed  and as stated above,  and noted in the stool chart . Rescue medication can not be 
taken during the  24 hrs before or after study medication. Any bowel movement produced 
within 24 hours of rescue medication will not be counted.   
In Stage 2,  rescue medication (Dulcolax suppository and/or enema)  can be taken on  demand 
during the run -in period  as stated above  and noted in the stool diary. During the dosing period, 
rescue medication is taken on the evening of the third dose at any given level if a stool has not 
been produced in response to three days of study medi cation . Enterin CMO should be consulted 
for any questions related to rescue medication.  Rescue medications will be recorded in the daily 
diary. Bowel movement produced within 24 hours of rescue medication will not be counted  as 
either spontaneous bowel movement or complete spontaneous bowel movement.  
 
• In both stages, p rotein pump inhibitors will be discontinued during the run -in period and 
reinstated during the wash -out period.   
•  Benzodiazepi[INVESTIGATOR_1651], hypnotics, other sedatives, barbitur ates, and opi[INVESTIGATOR_273712].  
All medications shall be reviewed and dis/approved by [CONTACT_30036] a case -by-case 
basis.  
• Selective serotonin reup take inhibitor (SSRI), SNRI,  tricyclic antidepressants  anti-
cholinergics , anti-histamines  and anti-psychotics  are permissible at stable doses.  
• Dopamine agonists and amantadine  will be  allowed if on a stable dose  for at least 4 weeks 
preceding the study . 
• Deep brain stimulation is allowed  at the PI’s discretion . 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  43 
 5 STRATIFICATION AND R ANDOMIZATION  (STAGE 2 ) 
 Participa nts will be randomly assigned to study drug or placebo in block sizes of 4 
according to a schedule provided by [CONTACT_4305]. Patients will be stratified according to 
constipation severity. We will compare results in patients with average complete  spontaneous 
stool frequency of 0 -1 per week with those of patients with an average frequency of 1 -2 per week. 
Patients will be blinded throughout the study until all data are analyzed and locked.  
6 UNBLINDING  
 Patients will be unblinded under the following circumstances : 
• Patient is terminated from the study  
• Patient drops -out of the study  
• A SAE occurs  
7 MATERIALS  
7.1 Study Drug  
 All study medications will be supplied by [CONTACT_273757]. Ent-01 will be supplied as 25mg tablets 
packaged in  white opaque high density polyethylene (HDPE) bottles with child -resistant closures . 
The placebo tablets will be identical in configuration and packaged similarly.  
7.[ADDRESS_334389] be stored in a locked, limited access area.  Both the used and unused 
study medication should be stored at  2 - 8°C (35.6 - 46.4°F).  
Identity of Investigational Products  
Product Name  [INVESTIGATOR_16139]-01 Placebo  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  44 
 Dosage form  Tablets (mg)  Tablet  
Dosage levels(mg)  25 Identical, but absent active  
Route/dosage  Oral. Doses above 25 mg will 
require multiple tablets:    
25 mg=1 tablet  
50 mg=2 tablets  
75 mg=3 tablets  
100 mg=4 tablets  
125 mg=5 tablets  
150mg=6 tablets  
175mg=[ADDRESS_334390] the house.  
9 STUDY PROCEDURES  
9.1 Sitzmarks assessment of colonic motility in Stage 2  
 On Day 8 of the run -in period and again on Day 3  of the randomized period, patients will 
be reminded to self -administer a Sitzmarks capsule (contains 24 radiopaque markers; Konsyl 
Pharmaceuticals, [LOCATION_007], [LOCATION_003]). The patient will be instructed to abstain from using suppositories 
or enemas if possible until  they return on Day 11 (or day 6 of randomized period). If they have to 
use suppositories on day 11 (or Day 6 of randomized period), make sure it’s recorded in the daily 
diaries. An abdominal XR will be scheduled for Day [ADDRESS_334391] 80% (19 or more of the markers) have grossly normal colonic 
transit. If remaining markers are scattered about the colon, the condition is most likely 
hypomotility or colonic inertia. If remaining markers are accumulated in the rectum or 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334392] patient to 
maximize liquid intake for the next two weeks.  
9.2 Observations and Measurements  
All the questionnaires will be fil led in according to the schedule. In Trail -Making B, the 
Trail will be completed twice, and both results will be reported. If the patient fails to complete the 
Trail, it will be reported as failed to complete.  
Stool diaries and sleep diaries: Patients will  be instructed how to fill the diaries daily 
throughout the study. They will be told to mark use of suppositories or enemas.  
           Vital signs : Per study procedures listings and for PK subjects Randomization Day [ADDRESS_334393] five days of the wash -out period, and will not be removed 
except for brief periods during a bath/shower. Patients will be shown how to wear the I-Button s 
with the button facing  the skin and overlying the radial artery.   
9.3 Informed Consent  
The Principal Investigator(s) at each center will ensure that the patient is given full and 
adequate oral and written information about the nature, purpose, possible risk and benefit of the 
study.  Patients must also be notified that they are free to disco ntinue from the study at any time.  
The patient should be given the opportunity to ask questions and allowed time to consider the 
information  provided.  
9.4 Instructions  to Patients  
Prior to entry into the study, patients and their spouse/companion will be taug ht how to fill 
in the daily diaries for stool and sleep. They will be instructed about the use of rescue medication 
and told to record it in the diary.  They will also be shown how to wear the   I-Button  and ho w to 
use the actigraphy device (See Appendix).  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  46 
 9.5 Clinical Laboratory Procedures  
The following tests will be obtained at  baseline and at the end of  each Period.  
• CBC  
• Chemistry  
• PT/PTT  
• Pregnancy test  
• Urinalysis  
PK Samples for 10 selected subjects:  
Timed blood samples (5.0 mL) will be collected into potassium -EDTA treated tubes for 
analysis of ENT -01 and its metabolite plasma concentrations.  
Blood samples for PK analysis will be collected at the following times before and after 
dosing on the day bef ore randomization and on Day 6 of the randomized period:  0 (pre -dose), 60 
min, 2, 4, 8 hrs.  
Once collected, PK samples will be stored in a -20ºC or -70ºC freezer until time of 
shipment.  Labels and appropriate shippi[INVESTIGATOR_273709].    
The concentration of study drug will be determined from the plasma samples using a 
validated analytical method.  Details of the method validation and sample analysis will be included 
with the final clinical study report.  
9.6 Other Procedures  
 Patients will fill in the following daily diary for stools (example inserted):  
Date  Dose mg  BM 
Yes/No  
 Consistency 
Modified Bristol 
Scale [ADDRESS_334394] lumps  
2.Lumpy sausage  
3.Cracked 
sausage  Ease of passage 
scale 1 -7 
1.Manual  
disimpaction  
2.Enema needed  
3.Straining 
needed  
4.Normal  Complete 
evacuation 
Yes/No 
 Suppository  
or laxative   
Yes/No/list 
med 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  47 
 4.Smooth 
sausage  
5.Soft lumps  
6.Mushy  
7.Watery  5.Urgent without 
pain 
6.Urgent with pain  
7.Incontinent  
3/20 - Yes 1 2 No Yes/suppos  
3/21 100 Yes 3 4 No No 
3/22 100 Yes 3 4 Yes No 
3/23 100 Yes 4 4 Yes No 
3/24 100 Yes 4 4 Yes No 
3/25 100 Yes 3 4 Yes No 
9.7 CTCAE Definitions  of Dose Limiting A dverse Events  
Adverse 
event  Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Diarrhea  
(watery 
stool)  Increase of <4 
stools a day 
over baseline  Increase of 4 -6 
stools a day 
over baseline  Increase of >7 
stools a day; 
incontinence; 
hospi[INVESTIGATOR_273713]; 
urgent 
intervention 
indicat ed Death  
Vomiting  1-2 epi[INVESTIGATOR_11644] 24 hrs  3-5 epi[INVESTIGATOR_11629] 
24 hrs  6 or more 
epi[INVESTIGATOR_211101] 24 
hrs; tube 
feeding, TPN or 
hospi[INVESTIGATOR_273714]-
threatening  
consequences ; 
urgent 
intervention 
indicated  Death  
Abdominal 
pain Mild  pain 
 Moderate  pain; 
limiting 
instrumental1 
ADL  
 Severe  pain; 
limiting self -
care ADL2 
 - - 
Postural 
hypotension3 Mild, transient 
lightheadedness 
or dizziness Moderate 
lightheadedness, 
dizziness or Severe 
lightheadedness, 
dizziness or Life-
threatening 
and urgent Death  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  48 
 upon rising 
from lying or 
sitting position 
that does not 
interfere with 
ADL  fainting upon 
rising from 
lying or sitting 
position that 
limits 
instrumental 
ADL;  Non-
urgent medical 
intervention 
indicat ed fainting upon 
rising from 
lying or sitting 
position that 
limits self -care 
ADL;  Medical 
intervention or 
hospi[INVESTIGATOR_273715] 
1Preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing money, etc.  
2Bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden  
3Definition adapted from combining CTCAE defin itions for Hypotension and Dizziness  
9.8 Criteria for  DLT  Endpoints : 
Recurrent vomiting:  3-5 epi[INVESTIGATOR_53287] 24 hours of taking ENT -01 (Grade 2 AE)  
Recurrent diarrhea:  4-6 epi[INVESTIGATOR_273716] 24 hours of taking ENT -01 (Grade 2 AE)  
Abdominal pain: Moderate pain that limits instrumental activities of daily living within 24  hours 
of taking ENT -01 (Grade 2 AE)  
Postural hypotension: Moderate dizziness, lightheadedness or fainting upon rising from lying to 
sitting  or standing  and severe e nough to require medical intervention within 24 hours of taking 
ENT -01 (Grade 2 AE)  or either a systolic blood pressure less than [ADDRESS_334395] Parkinson’s disease. Specific pre -existing 
medical conditions that will be exclu ded are listed in patient exclusion criteria.  
9.10 Treatment Emergent Adverse events  
Treatment -emergent adverse event (TEAE) is defined as any event not present prior to the 
initiation of the treatments or any event already present that worsens in either intensity or 
frequency following exposure to the treatments.  
AE is typi[INVESTIGATOR_273717] d rug. TEAE is for after the subject actually taking the study drug.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  49 
 AEs may be called “baseline -emergent adverse event” which is defined as any event which occurs 
or worsens during the staged screening process (after informed consent) including the 
randomiz ation visit. We will include separate summaries for AEs that occur prior to the initiation 
of the treatment and AEs that occur after the initiation of the treatment ( i.e., summary of treatment 
emergent adverse events).  
9.11 Laboratory Abnormalities  
 Clinical la bs will be performed by a local laboratory.  Labs to be drawn during the study 
include: serum chemistries, a hematology panel and urinalysis.  A serum pregnancy test must be 
performed and the result must be negative prior to the entry of women of child bea ring potential.  The 
investigator must obtain verification that the local laboratory meets the standards for quality and 
consistency set by [CONTACT_9891].  
 Clinical laboratory reports must be reviewed by a physician for out -of-range values within 24 
hours of receipt.   Out -of-range values will be evaluated using the following notations:  
 • NS Not clinically significant  
 • LE Laboratory Error  
 • PT Patient abnormal; relates to the patient's usual state of health  
 • SG Significant, othe r.  This value cannot be explained by [CONTACT_273758].  
 By [CONTACT_108] a lab value flagged as "SG" must be entered on the adverse clinical laboratory 
event page in the case report form.  A laboratory test flagged "SG" must be repeated as soon as 
possible.  The investigator may use his/her own judgment as to whether the abnormal finding is 
sufficient reason to immediately withdraw the patient from the study.  
 If a laboratory value is considered to be serious and life -threatening the patient should be 
immediately discontinued from the study and appropriate therapy started.  Refer to sections 9.7-9.12 
for definition of a serious adverse event and related terms, and to section s 9.13-9.16 for details on 
reporting a serious adverse event.  
9.12 AE Assessment and Recording  
All adverse events, exacerbations of concomitant illnesses, or events known to be related 
to underlying disease processes or concomitant medications are to be recorded on the case report 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334396] also assess whether the event was r elated to the 
study medication, concurrent drug therapy, underlying disease, a combination of these factors, or 
if it is unknown.  Patients with an adverse event should be carefully followed to determine 
outcome.   
The investigator will use the NCI definit ions to grade the severity  of the event.  
Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated  
Grade 2:  Moderate ; minimal, local, or non -invasive intervention indicated; limiting age -
appropriate ADL  
Grade 3: Severe  or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care ADL.  
Grade 4:  Life-threatenin g consequences;  urgent intervention  indicated  
Grade 5: Death  
The relationship or association of the study medication in causing or contributing to the 
adverse event will be characterized as remote, possible or probable as defined below:  
Not related : Evidence indicates no plausible direct relationship to the  study medication  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  51 
 Remote : Suggests other conditions are reasonably likely to account for the event including 
concurrent illness, progression or expression of the disease state, or reaction to concurrent 
medication  
Possible : Suggests that the association of  the event with the study medication is unknown; 
however, the adverse event is not reasonably supported by [CONTACT_273759] : Suggests that a reasonable temporal sequence of the event with medication 
administration exists and, based upon the invest igator's clinical experience, the association 
of the event with study medication seems likely  
Definite: Suggests that based upon the investigator’s experience, the association of the 
event with the study medication seems very certain.  
Procedures such as s urgery should not be recorded as adverse events.  However, the 
medical condition for which the procedure was performed should be reported if it meets the 
definition of adverse event.  
9.[ADDRESS_334397] of adverse events may not be used during this study.  
 The following are specific definitions that are relevant to meeting your reporting obligations 
and which are included in the FDA Regulations, 21CFR Part 312.32, and International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(ICH) Guidelines:  
Adverse Event :  Any untoward medical occurrence in a patient administered a 
pharmaceutical product and which does not necessarily have to have a causal relationship with 
this treatment.  An adverse event can be any unfavorable sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of the 
investiga tional drug, whether or not considered related to the investigational drug.  
Serious Adverse Event : An untoward event or reaction that at any dose:  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  52 
 • results in death  
• is life -threatening  
• requires inpatient hospi[INVESTIGATOR_059]  
• prolongs existing hospi[INVESTIGATOR_059]  
• results in permanent or significant disability or incapacity  
• is a congenital anomaly/birth defect  
• requires intervention to pre vent permanent impairment/ damage  
Life-threatening : An event which a patient was at risk of death at the time of event.  
 There is a distinction between the severity and the seriousness of an adverse event.  Severe is 
a measurement of intensity, thus a severe reaction is not necessarily a serious adverse event.  For 
example, a headache may be severe in intensity, but would not be seriou s unless it met one of the 
criteria for serious adverse events listed previously.  
9.14 Serious Adverse Events  
Adverse events (AEs) and serious adverse events (SAEs) will be collected from the start 
of study treatment until the follow -up contact. Medical occurre nces that began prior to the  start of 
study treatment, but after obtaining informed consent were recorded on the  Medical 
History/Current Medical Conditions CRF. The investigator or site staff will be responsible for the 
detection and documentation of event s meeting the criteria and  definition of an AE or SAE, as 
provided in the study protocol , 
However, any SAEs assessed as related to study participation (e.g., dosing, protocol 
mandated procedures, invasive tests, or change in existing t herapy) or related to  a concomitant 
medication will be recorded from the time a subject consents to participate in  the study up to and 
including any follow -up contact.  
In the event of an AE or SAE, it will be the responsibility of the Investigator to review all  
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) relative  to the 
event and attempt to establish a diagnosis of the event based on signs, symptoms,  and other clinical  
information. The diagnosis was to be documented as the AE/SAE and  not t he individu al’s 
signs/symptoms. Once an Investigator becomes aware that an SAE has  occurred  in a study subject, 
they are ' to report the information to Enterin within 24hrs and  provide an assessment of causality.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  53 
 9.15 Notification of Serious Adverse Events  
Under  IND regulations, 21 CFR Part 312.64, investigators are required to notify the 
Sponsor promptly , within 24 hours of the sites’ notification  of any serious adverse events, deaths, 
or life -threatening problems with the investigational drug.  This regulation also requires that if the 
adverse event is alarming, the investigator must notify the Sponsor immediately.  
The Sponsor must be notified as detailed in section  9.16, "Reporting a Serious Adverse 
Event."  The Sponsor, in turn, will report all serious adverse events to regulatory agencies as 
required.  In addition to the serious adverse events described in  section  9.7, other events that in the 
investigator's opi[INVESTIGATOR_196402] a significant hazard, contraindication, or precaution should be 
considered serious.  This incl udes, but is not limited to, blood dyscrasias, endocrine disturbances, 
hemorrhage from any site, or severe skin disorder . Additional examples are intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions  that do 
not result in hospi[INVESTIGATOR_059], and development of drug dependency or drug abuse.  Hospi[INVESTIGATOR_273718] a serious adverse event.  In addition, pregnancy is not a 
Serious Adverse Event, but is reportable and must be reported per IND regulations and timelines, 
[ADDRESS_334398] be reported immediately (within 
one business day) via telephone/ email  to: 
Safety@Enteri nInc.com  
and   
 Denise Barbut MD FRCP  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  54 
   [EMAIL_5356]  
                       [EMAIL_5357]  
  Cell [PHONE_5677]  
 And 
  Michael Zasloff MD PhD  
  [EMAIL_5358]   
  Cell [PHONE_5683]  
 And  
  Heidi Marcus Moran  
  [EMAIL_5359]  
  Cell [PHONE_5684]  
Enterin Inc : Phone Number:  [PHONE_5685]  
Specific medical questions can be addressed to the Chief M edical Officer : 
  Denise Barbut, M.D , FRCP.  
  President and Chief Medical Officer  
  Phone ([PHONE_5677] ) 
 The back -up medical monitor, to be contact[CONTACT_273760], is:  
  Michael Zasloff, MD, Ph.D  
  Chairman and CEO  
  Phone ([PHONE_5683] ) 
 The initial report should contain as much information as is available concerning the event 
in order to permit the Sponsor to file a report that satisfies regulatory requirements.  Initial 
telephone reports of serious adverse events must be followed -up by a  fax of a completed SAE 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334399] (IRB).  
9.17 Serious Adverse Experiences: After Study Participation  
Preclinical data to date do not point to specific classes of adverse events for which patients may 
be at risk after completion of study participation.  In order to monitor for unanticipated adverse 
events occurring after study participation, the following mus t be complied with:  
• Any occurrence of a patient death is to be reported any time that the investigator 
becomes aware of the event  
• A congenital anomaly in an offspring of a patient where that offspring has been 
born after the patient used study medicati ons should be reported  
• Any serious adverse event, for which, in the investigator's opi[INVESTIGATOR_1649], there is a 
reasonable possibility that the event could have been caused by [CONTACT_5257], should be 
reported  
• Any other serious adverse event should be reported  if it occurred within thirty days 
following the last dose of study medication  
9.[ADDRESS_334400] describe the departure from the protocol 
and state the reason.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334401]  
A Data Safety and Monitoring Committee (D SMB ) has  been established to monitor the 
safety of the subjects during the course of the study .  The D SMB include s members with relevant 
clinical expertise, including a good understanding of the safety of medications for Parkinson’s 
disease . These members include a statistician, a gastroenterologist and a neurologist. The 
methodology and the operating procedures for the safety reviews will be developed by [CONTACT_273761] D SMB Charter.  
9.[ADDRESS_334402] some (“STDE dose”). When the first ten subject s in Stage [ADDRESS_334403] be submitted to the IRB.  Protocol 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334404] of 10 patients who will be 
dose escalated in single doses. Each patient will proceed through all the dose escalations starting 
at 25 mg and ending at 200 mg or at the dose at which s/ he experiences a dose limiting toxicity 
(DLT). The doses to be tested are 25mg, 50mg, 75mg, 100mg, 125mg, 150mg,  175mg  and 200mg. 
In the Stage 2 portion, all patients will go through a multiple dose escalation (3 dosing days at each 
dose) and the dose at w hich the patient experiences a consistent pro -kinetic effect (spontaneous, 
complete stool in at least 2/3 consecutive doses) without a DLT will be the dose for that patient. 
Patients who experience a DLT prior to reaching their pro -kinetic dose and at a do se equal to or 
less than the STDE dose will be terminated. Otherwise the patient will be assigned the highest 
dose at which they did not experience a DLT. If the patient reached 175 mg without a DLT and 
without a pro -kinetic dose, her/his dose will be 175 mg. The primary endpoint for the Stage 1 study 
is to determine whether the dose levels explored are safe and tolerable. The primary endpoint for 
the Stage 2 study is the regularization of bowel function as determined by  [CONTACT_273762] . The Stage 2 portion will enroll 40 patients, with 
a target sample size of 34 evaluable patients. Six extra patients are enrolled to allow for patient 
withdrawals  or terminations  prior to the completion of the trial.  
10.1 Sample Size/Power Considerations  
10.1.1   Stage  1 
There will be 10 patients enrolled in Stage 1. Two patients will be started on the 25mg 
dose. If no DLTs are observed, they will be escalated to the next dose and the remaining 8 patients 
will be started at 25mg. E ach dose level will be a single dose and patients will be observed for 
three days before being given the next higher single dose. It is intended that each patient receive a 
single dose of each of the levels: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg and 200mg. 
However, if a patient experiences a DLT, they will not be further escalated.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  58 
  A DLT is defined  in Section 9.8 using the Common Terminology Criteria for Adverse 
Events (CTCAE), as a grade 2 vomiting within 24 hours of taking ENT -01 grade 2 diarrhea within 
24 hours of taking ENT -01, grade 2 abdominal p ain within 24 hours of taking ENT -01, grade 2 
postural hypotension within 24 hours of taking ENT -01. Additionally, an LFT elevation > 3xULN 
within 24 hours of taking ENT or any gastrointestinal AE > grade [ADDRESS_334405]  possibly attributable to ENT -01 will be considered dose -limiting toxicity 
for the pur pose of analyses.  
There is no power calculation for the Stage 1 portion because it is merely trying to 
determine whether ENT -01 is safe and tolerable for these levels. Th e PK analyses will be 
descriptive and are meant to understand how ENT -01 is metabolized.  
10.1.2  Stage  2 
The target sample size for Stage 2  is 34 evaluable patients and an additional 6 patients will 
be accrued to allow for patient drop -outs and terminations ; these 40 patients will be different from 
the 10 patients accrued to Stage 1. A patient is evaluable if s/he has baseline measurements 
(obtained at the end of the run -in Period, 3.1) and measurements at the end of the fixed dose  period 
(end of Period 3.2). The primary endpoint for Stage 2 is average complete spontaneous stool 
frequency increase by 1 point  over baseline , OR 3 or more complete spontaneous stools per week . 
A patient will be labeled as a “success” if s/he meets one or more of  the criteri a abov e, otherwise 
the patient will be labeled as a “failure”. The primary analysis compare s the proportion of patients 
deemed a success at the end of the fixed -dose period  (end of period 3.2) to 0.10, which is the 
highest proportion of spontaneous resolution of  constipation assuming no treatment . A patient is 
deemed a success or failure by [CONTACT_23992] t he assessment at the end of the  fixed -dose period 
(Period 3.2) to baseline (obtained at the end of the run -in period, Period 3.1). There could be 
between 34 and 40 patients with these measurements and each patient will be labeled as a “success” 
or “failure”. It is assumed that without treatment, the success rate would be 10% (null hypothesis). 
An exact binomial test with a 0.[ADDRESS_334406] 80% power to detect the 
difference between 0.10  (proportion expected if patients are not treated), p 0, and a n ENT -01 
proportion, p E, of 0. 29 (0.27) when the sample size is 34 (40). It is assumed that most  patients will 
be deemed a success on the ENT -01 arm and so the study is adequately powered.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  59 
 10.2 Data Collection and Case Report Form Monitoring  
Reports will be generated on a weekly basis to monitor data completeness. Sites and 
patients who are missing data will be contact[CONTACT_273763] r esolve any obstacles 
regarding the data submission.  
10.3 Endpoint definitions and measurements  
10.3.1  Assessment of Safety  
Safety assessments (vital signs, physical examinations, interim medical history, vital signs, 
EKG (when clinically war ranted for any unscheduled EKG) , AEs, clinical laboratory results 
(routine hematology and biochemistry) are to be performed at protocol -specified visits, as 
specified in the Schedule of Procedures and Assessments.  
 Vital Signs  
Vital signs (body temperature, respi[INVESTIGATOR_1487], heart rate, systolic and diastolic blood 
pressure measurements) will be evaluated at the visits indicated in the Schedule of Procedures and 
Assessments.  Blood pressure will be taken twice.  The first time, the patient shall be lying down.  
The second blood pres sure will be taken within [ADDRESS_334407] 5 minutes.  Blood pressure measurements are to be taken in  the same arm for 
the duration of the study.   Body weight (without shoes) will be recorded whenever vital signs are 
recorded, and height (without shoes) will be recorded at screening only.  
Vital sign measurements will be repeated if clinically significant or machine/equipment 
errors occur.  Any confirmed, clinically significant vital sign measurements must be recorded as 
AEs.  
 Physical Examination  
A complete physical examination (head, eyes, ears, nose and throat, heart, lungs, abdomen, 
skin, cervical and a xillary lymph nodes, neurological, and musculoskeletal systems) will be 
performed at Visit 1.  Physical examinations will be performed by a physician.  In addition, 
medical history will be recorded at screening, including smoking history, if applicable.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  60 
 A limited (brief) physical examination to verify continued patient eligibility and to follow 
up any change in medical history will be performed at the visits indicated in the Schedule of 
Procedures and Assessments.  Symptom -driven limited physical examinati ons will be performed 
as clinically indicated at any study visit.  All changes not present at baseline or described in the 
past medical history and identified as clinically noteworthy must be recorded as AEs.  
 Electrocardiogram (EKG)  
A [ADDRESS_334408] be filed with 
both the patient's CRF and medical  record (source document) for that visit. Any laboratory test 
result considered by [CONTACT_80213] 
(clinically significant AEs include those that require an intervention). Clinically significant 
abno rmal values occurring during the study will be followed until repeat test results return to 
normal, stabilize, or are no longer clinically significant.  
Adverse events  
All reported AEs will be coded using the  CTCAE version 4.03 terminology .  The incidence 
of treatment -emergent AEs (TEAEs; events with onset dates on or after the start of the study drug) 
and treatment -related AEs will be summarized by [CONTACT_9313] (SOC) and preferred term 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  61 
 (PT).  Events with missing onset dates will be included as treatme nt-emergent.  If a patient 
experiences more than [ADDRESS_334409] will 
be summarized by [CONTACT_3592]; categories of AEs of special interest include: nausea, vomiting, 
abdominal pain, diarrhea, and rectal bleeding.  
All AEs will be listed by [CONTACT_4676], along with inf ormation regarding onset, duration, 
relationship and severity to study drug, action taken with study drug, treatment of event, and 
outcome . 
10.3.2  Efficacy Endpoints  
 Frequency of bowel movements:  
The frequency of bowel movements will be determined via a daily di ary where the passage 
of a bowel movement or absence thereof will be recorded daily  throughout the study. Bowel 
movements that are the consequence of a rescue medication or suppository will not be counted  
if they occur within 24 hours of the rescue medication or suppository . Epi[INVESTIGATOR_273719].   
Success will be defined as a n average  complete spontaneous stool frequ ency increase by 
1/week or more compared to baseline  or 3 or more  complete spontaneous stools/week . Baseline 
will be the run -in period weekly average and treatment period will be determined as the weekly 
average during the fixed dose (40 patients) treatment  period.  
Colonic Motility:  
Colonic motility will be determined using the Sitzmarks technique at the beginning of the 
run-in period and again at the end of the  randomized treatment period during Stage 2. The primary 
measure of interest is the mean colonic transit (MCT) time estimated with a single film (Metcalf 
et al.,  1987).  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  62 
 10.4 Analysis Plan  
10.5 Stage 2 
Primary analysis : The AE information for the Stage 2 portion of the trial will be 
summarized as frequency and relative frequency by [CONTACT_273764].  
The primary efficacy outcome variable is whether or not a patient is a “success” or 
“failure”. This is a n endpoint based on patient diary entries for the week prior to the endpoint 
assessment defined as average  complete stool frequency increase by 1 or more over baseline , OR 
3 or more complete sp ontaneous stools/week.  The patient is deemed a “success” if s/he meets one 
or more of  the criteri a listed above, otherwise the patient will be deemed a “failure”. The primary 
analysis will be based on all patients with a baseline assessment (the end of the  run-in period, 
Period 3.1) and an assessment at the end of the fixed -dose period (Period 3.2) and will be a 
comparison of the proportion of successes with 0.10 (the null hypothesis corresponding to no 
treatment effect).  The proportion of patients for whom  the drug was a success at the end of period 
3.2 will be estimated with a binomial point estimate and corresponding 95% confidence interval. 
The observed proportion of success es will be compared to 0.[ADDRESS_334410]. ENT -
01 will be deemed a s demonstrating sufficient efficacy if the two -sided p -value is less than 0.05 
for this comparison.  
Seconda ry analyses :  
A secondary  analysis will compare the proportion s of patients who are deemed a success 
at the end of the randomized period (Period 4) as compared to baseline (end of the run -in period, 
Period 3.1)  between those randomized to the ENT -[ADDRESS_334411] a baseline assessment  (end of 
the run -in peri od) and an assessment at the end of the randomization period  of the trial, which 
could be between 34 and 40  patients (17 to 20 in each arm).  A Fisher’s exact  test will be used to 
compare the proportion s of patients who are deemed a success at the end of randomization period 
(period 4) between the two randomized arms.  Another secondary analysis will compare the 
proportions of patients who are a success (compared to baseline) between the end of the first week 
of the washout period (period 5) to the end of t he randomization period (period 4), for those 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  63 
 patients who were randomized to receive ENT -01 (between 17 and 20 patients). This analysis will 
consist only of those patients with assessments at baseline (end of run -in period, Period 3.1), the 
end of Period 4, and the end of Period 5. This analysis will have between [ADDRESS_334412] of equality of paired proportions.  
Exploratory analyses :  
The first exploratory analysis will of the  colonic motility values  as measur ed by [CONTACT_273765] . Comparisons will be made within each patient at different time points 
(i.e. baseline and the end of fixed period) as well as between patient groups (i.e. values observed 
at the end of randomization period, period 4 for the placebo and the ENT -01 treated groups) . The 
primary endpoint for this analysis is the MCT based on a single film estimate. From a previous 
study (Ashraf et al., 1997), and estimate for the average MCT for constipated patients with 
Parkinson’s disea se is 53.[ADDRESS_334413] at the end of the fixed period from baseline.  
A sample size of 34 (40) patients will have 80% power to detect a mean ch ange of 11.1 hours (10.2 
hours) with a 0.[ADDRESS_334414] to the sleep data,  the body temperature 
data, mood , fatigue, hallucinations , overall NMS scale  and all other questionnaires and  neuro -
cognitive tests . These parameters will be summarized numerically and graphically. There will also 
be compariso ns done of changes over time within a patient (i.e. between baseline, end run -in 
period, and at the end of the fixed dose period, Period 3.2) and differences between groups (i.e. 
between patients in the Enterin arm and in the placebo arm at the end of peri od 4). As before, 
continuous measurements within a patient will be compared with a paired t -test (transforming the 
data if necessary) and continuous measurements between patient groups will be compared with a 
two-group t -test (transforming the data if nece ssary). In addition, these data will be analyzed using 
a mixed linear model since there are multiple measurements over time. Categorical data will be 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334415] or a Fisher’s exact test if the expected cell counts are too small 
for a chi-squared test.  
[ADDRESS_334416] patient out is expected to be 9 -12 
months.  
12 ADMINISTRATIVE PROCE DURES AND ETHICAL CO NSIDERATIONS  
12.1 Medical Care  
This study has an estimated duration of  21 weeks. During this period, patients will be on 
medication for a maxim um of eight  weeks. None of the patients will be given medicat ion during 
the run -in period or  the wash -out period.  
12.2 Patient Information and Informed Consent  
The Principal Investigator(s) a t each center will ensure that the patient is given full and 
adequate oral and written information about the nature, purpose, possible risk and benefit of the 
study.  Patients must also be notified that they are free to discontinue from the study at any ti me.  
The patient should be given the opportunity to ask questions and allowed time to consider the 
information provided.  
The patient’s signed and dated informed consent must be obtained before conducting any 
study procedures.  
The Principal Investigator(s) must maintain the original, signed Informed Consent Form.  
A copy of the signed Informed Consent Form must be given to the patient.  
12.3 Study Monitoring  
Before an investigational site can enter a patient into the study, a representative of Enterin, Inc. 
will v isit the investigational study site to:  
• Determine the adequacy of the facilities  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  65 
 • Discuss with the investigator(s) and other personnel their responsibilities with regard to 
protocol adherence, and the responsibilities of Enterin, Inc. or its representatives.  This will 
be documented in a Clinical Study Agreement between Enterin, Inc. and the investigator.  
During the study, a monitor from Enterin, Inc. or representative will have regular contacts with 
the investigational site, for the following : 
• Provide information and support to the investigator(s)  
• Confirm that facilities remain acceptable  
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that investigational  product accountability 
checks are being performed  
• Perform source data verification.  This includes a comparison of the data in the case report 
forms with the patient’s medical records at the hospi[INVESTIGATOR_7117], and other records 
relevant to the study.  This will require direct access to all original records for each patient 
(e.g. clinic charts).  
• Record and report any protocol deviations not previously sent to Enterin, Inc. 
• Confirm AEs and SAEs have been properly documented on CRFs and confirm any SAEs 
have been forwarded to Enterin, Inc. and those SAEs that met criteria for reporting have 
been forwarded to the IRB.  
The monitor will be available between visits if the investigator(s) or other staff needs 
information or advice.  
12.[ADDRESS_334417] may visit the site to perform audits or inspections, 
including source data verification.  The purpose of an Enterin, Inc. audit o r inspection is to 
systematically and independently examine all study -related activities and documents to determine 
whether these activities were conducted, and data were recorded, analyzed, and accurately reported 
according to the protocol, Good Clinical Practice guidelines of the International Conference on 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334418] submit written approval to Enterin Inc. before he or she can e nroll any 
patient/subject into the study.  
The Principal Investigator [INVESTIGATOR_273720].  In addition, the IRB or IEC must approve 
all advertising used to recru it patients for the study.  The protocol must be re -approved by [CONTACT_49918], as local regulations require.  
The Principal Investigator [INVESTIGATOR_273721] s adverse drug reactions from any other study conducted with the investigational 
product. Enterin, Inc. will provide this information to the Principal Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to th e 
IRB or IEC according to local regulations and guidelines.  
12.[ADDRESS_334419] their origin in 
the Declaratio n of Helsinki and are consistent with ICH/Good Clinical Practice, applicable 
regulatory requirements and Enterin, Inc.’s policy on Bioethics.  
12.[ADDRESS_334420] will not be identified by [CONTACT_2300], only by [CONTACT_5657]/her initials.  The subject’ s name [CONTACT_273769] a result of this study.  
However, information obtained from individual subject’s participation in the study may be 
disclosed with his/her consent to the health care providers for the purpose of obtaining appropriate 
medical care.  The subject ’s medical records/charts, tests with his/her name [CONTACT_273770]1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334421] research organization (CRO), the sponsor, its potential 
eventual partners, and a ny other regulatory authorities.  This is for the purpose of verifying 
information obtained for this study.  Confidentiality will be maintained throughout the study within 
the limits of the law.  
A subject’s name [CONTACT_273771], 
who have pledged an oath of confidentiality.  All identifying information will be kept behind 
locked doors, under the supervision of the study Investigator and will not be transferred outside of 
the investigator site.  
A subject  may take away his/her permission to collect, use and share information about 
him/her at any time.  If this situation occurs, the subject will not be able to remain in the study.  
No new information that identifies the subject will be gathered after that d ate.  However, the 
information about the subject that has already been gathered and transferred  may still be used and 
given to others as described above in order to preserve the scientific integrity and quality of the 
study.  
12.[ADDRESS_334422] or other designated individual will maintain records of study treatment 
delivered to the study site; the inventory at the site; the distribution to and use by [CONTACT_6904]; and 
the return of materials to Enterin, Inc. for storage or disposal. These reco rds should include dates, 
quantities, batch/serial numbers, expi[INVESTIGATOR_1659], in -clinic temperature log, and unique code 
numbers assigned to the product and study patients.   
At each visit after initiation of treatment, site staff will record compliance of  patients with 
their assigned regimen.  Patients will be instructed to bring their diaries and cartons containing 
unused/partially used/empty vials back for inspection at each study visit. Patients are to be 
reminded of the importance of compliance with th eir assigned regimen, with an emphasis on taking 
their study drug on schedule, and maintaining the prescribed interval between doses.  
Investigator will maintain records that document adequately that the patients were provided 
with the correct study drug an d will reconcile the products received from the drug dispensing 
center. Investigational product will not be returned to Enterin, Inc. until accountability has been 
fully monitored.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334423] be returned at each visit, as compliance will be  assessed by 
[CONTACT_204265]. Noncompliance is defined as taking less than 80% or more than 120% of study drug 
during any outpatient evaluation period (visit to visit). Discontinuation for noncompliance is at the 
Investigator’s discretion and is to be noted on the case report form (CRF).  
12.[ADDRESS_334424] be read thoroughly and the instructions followed exactly.  The sponsor 
and/or designee will not grant waivers for protocol deviations.  Any deviation to the protocol has 
to be reported as soon as possible to the sponsor.  The governing r eporting guidelines for protocol 
deviations must be adhered to by [CONTACT_737].  
12.11  Study Termination  
This study may be prematurely terminated, if in the opi[INVESTIGATOR_273722], there 
is sufficient reasonable cause.  Written notification do cumenting the reason for study termination 
will be provided to the Investigator or Enterin by [CONTACT_51272].  Circumstances that may 
warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk  to subjects.  
• Failure to enroll subjects at an acceptable rate.  
• Insufficient adherence to protocol requirements.  
• Insufficient complete and/or evaluable data.  
• Plans to modify, suspend, or discontinue the development of ENT -01. 
Should the study be closed prematurely, all study materials must be returned to Enterin.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334425] should be indicated by [CONTACT_2224] "NA".  Spaces should not be left blank.  Electronic case report 
forms will be reviewed during the monitoring visits.  Data will be entered into a database.  Data entry 
and management and the production of the clinical study report will be the responsibility of the 
sponsor or a designated agent.  
 The data cut -off for the study will be [ADDRESS_334426].  It is the Investigator’s resp onsibility 
to ensure the accuracy, completeness, and timeliness of the data entered in each subject’s eCRF.  
Source documentation supporting the eCRF data should indicate the subject’s participation in the 
study and document the dates and details of study procedures, AEs, and subject status.  
The Investigator, or designated representative, should complete the eCRF as soon as 
possible after information is collected, preferably on the same day that a subject is seen for an 
examination, treatment, or any other study procedure. The information collected from the daily 
sleep and stool diaries will be entered by [CONTACT_3210] a designated representative on an on -going 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334427] 15 years after the 
completion or discontinuation of /withdrawal from the study or [ADDRESS_334428] approval of a 
marketing application in an ICH region, whichever is the longer time period.  
The Investigator agrees to comply with all applicable federal, state, and local laws and 
regulations relating to  the privacy of patient health information, including, but not limited to, the 
Standards for Individually Identifiable Health Information, 45 CFR, Parts 160 and 164 (the Health 
Insurance Portability Accountability Act of 1996 [HIPAA] Privacy Regulation). T he Investigator 
shall ensure that study patients authorize the use and disclosure of protected health information in 
accordance with HIPAA Privacy Regulation and in a form satisfactory to the Enterin, Inc.  
12.[ADDRESS_334429] 
of institution’s or In vestigator’s activities related to this study from a regulatory authority, the 
Investigator must immediately notify the sponsor and the appropriate CRO of the request.  
Following this inspection and/or audit, the Investigator must notify the sponsor of any  violation or 
deficiency noted by [CONTACT_46962].  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  71 
 13 USE OF INFORMATION      
Both the use of data and the publication policy are detailed within the clinical study 
agreement. Intellectual property rights (and related matters) generated by [CONTACT_273766] a clinical study agreement that 
will be agreed between the Institution and Enterin, Inc. or their designee. With respect to such 
rights, Enterin, Inc. or its designee will solel y own all rights and interests in any materials, data, 
and intellectual property rights developed by [CONTACT_202861], patient to the terms of any such agreement. In order to facilitate such 
ownership, Investigators will be required to assign all such inventions directly to Enterin, Inc. or 
its designee, as will be set forth in the clinical study agreement.  
[ADDRESS_334430] read the foregoing protocol “A Multicenter, Single -dose, Multiple -dose, Randomized, 
Double -blind, Placebo -controlled study to evaluate Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of orally administered ENT -01 for Constipation in Parkinson’s disease ” and 
agree to conduct the study as described the rein. 
 
[name]     
Investigator’s Name     
    
  [dd/mm/yyyy]   
Investigator’s Signature   [CONTACT_273772]1001  v0.9,  Version Date: 27JUL2017  72 
 15 REFERENCES  
Allen Reish, H.E., Standaert, D.G., 2015. Role of alpha -synuclein in inducing innate and adaptive 
immunity in Parkinson disease. Journal of Parkinson's disease 5, 1 -19. 
Bhargava, P., Marshall, J.L., Dahut, W., Rizvi, N., Trocky, N., Williams, J.I., Hait, H., Song, S., 
Holroyd, K.J., Hawkins, M.J., 2001. A phase I and pharmacokinetic study of squalamine, a novel 
antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 7, 3912 -3919.  
Bouras, E.P., Tangalos, E.G., 2009. Chronic constipation in the elderly. Gastroenterology clinics 
of North America 38, 463 -480. 
Braak, H., de Vos, R.A., Bohl, J., Del Tred ici, K., 2006. Gastric alpha -synuclein immunoreactive 
inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease -related 
brain pathology. Neuroscience letters 396, [ADDRESS_334431], M.J., 2006. Squalamine lactate for 
exudative age -related macular degeneration. Ophthalmol Clin North Am 19, 381 -391, vi.  
Edwards, L.L., Pfeiffer, R.F.,  Quigley, E.M., Hofman, R., Balluff, M., 1991. Gastrointestinal 
symptoms in Parkinson's disease. Movement disorders : official journal of the Movement Disorder 
Society 6, 151 -156. 
Furness, J.B., Kunze, W.A., Clerc, N., 1999. Nutrient tasting and signaling mechanisms in the gut. 
II. The intestine as a sensory organ: neural, endocrine, and immune responses. The American 
journal of physiology 277, G922 -928. 
Greene, J.G., 2014. Causes and consequences of degeneration of the dorsal motor nucleus of the 
vagus ner ve in Parkinson's disease. Antioxidants & redox signaling 21, [ADDRESS_334432], R.S., Hammond, L.A., Carbone, D.P., Tran, H.T., Holroyd, K.J., Desai, A., Williams, J.I., 
Bekele, B.N., Hait, H., Allgoo d, V., Solomon, S., Schiller, J.H., 2003. A phase I/IIA trial of 
continuous five -day infusion of squalamine lactate (MSI -1256F) plus carboplatin and paclitaxel in 
patients with advanced non -small cell lung cancer. Clin Cancer Res 9, 4108 -4115.  
Kararli, T.T ., 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of 
humans and commonly used laboratory animals. Biopharm Drug Dispos 16, 351 -380. 
Klingelhoefer, L., Reichmann, H., 2015. Parkinson's Disease and Gastrointestinal Non Motor 
Symptoms: Diagnostic and Therapeutic Options - A Practise Guide. Journal of Parkinson's disease 
5, 647 -658. 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  73 
 Lewis, S.J., Heaton, K.W., 1997. Stool form scale as a useful guide to intestinal transit time. 
Scandinavian journal of gastroenterology 32, 920 -924. 
Li, A.C., Sabo, A.M., McCormick, T., Johnston, S.M., 2004. Quantitative analysis of squalamine, 
a self -ionization -suppressing aminosterol sulfate, in human plasma by [CONTACT_29864] -MS/MS. Journal of 
pharmaceutical and biomedical analysis 34, 631 -641. 
Lin, C.H., Lin, J.W., Liu, Y.C., Chang, C.H., Wu, R.M., 2014. Risk of Parkinson's disease 
following severe constipation: a nationwide population -based cohort study. Parkinsonism & 
related disorders 20, [ADDRESS_334433], J. N., Jr., McCrimmon, D., Zasloff, M., 
1993. Squalamine: an aminosterol antibiotic from the shark. Proceedings of the National Academy 
of Sciences of the [LOCATION_002] of America 90, [ADDRESS_334434] inhibits the initiation of alpha -
synuclein aggregation and suppresses its toxicity. Proceedings of the National Academy of 
Sciences of the [LOCATION_002] of America.  
Recchia, A., Debetto, P.,  Negro, A., Guidolin, D., Skaper, S.D., Giusti, P., 2004. Alpha -synuclein 
and Parkinson's disease. Faseb J 18, 617 -626. 
Sahay, S., Ghosh, D., Singh, P.K., Maji, S.K., 2016. Alteration of Structure and Aggregation of a -
Synuclein by [CONTACT_273767]'s Dise ase Associated Mutations. Current protein & peptide 
science.  
Salat -Foix, D., Suchowersky, O., 2012. The management of gastrointestinal symptoms in 
Parkinson's disease. Expert review of neurotherapeutics 12, [ADDRESS_334435] temperature 
in normal -living subjects A candidate of new index of the circadian system. Physiology & behavior 
95, 570 -580. 
Savica, R., Carlin, J.M., Grossardt, B.R., Bower, J.H., Ahlskog, J.E., Maraganore, D.M. , 
Bharucha, A.E., Rocca, W.A., 2009. Medical records documentation of constipation preceding 
Parkinson disease: A case -control study. Neurology 73, 1752 -1758.  
Sharma, V., McNeill, J.H., 2009. To scale or not to scale: the principles of dose extrapolation. 
British journal of pharmacology 157, 907 -921. 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  74 
 Shi, Z., Sachs, J.N., Rhoades, E., Baumgart, T., 2015. Biophysics of alpha -synuclein induced 
membrane remodelling. Physical chemistry chemical physics : PCCP 17, [ZIP_CODE] -[ZIP_CODE].  
Sumioka, A., Yan, D., Tomita, S., 2 009. TARP phosphorylation regulates synaptic AMPA 
receptors through lipid bilayers. Neuron 66, 755 -767. 
Sung, H.Y., Park, J.W., Kim, J.S., 2014. The frequency and severity of gastrointestinal symptoms 
in patients with early Parkinson's disease. Journal of movement disorders 7, 7 -12. 
van Marken Lichtenbelt, W.D., Daanen, H.A., Wouters, L., Fronczek, R., Raymann, R.J., 
Severens, N.M., Van Someren, E.J., 2006. Evaluation of wireless determination of skin 
temperature using iButtons. Physiology & behavior 88, 48 9-497. 
Visanji, N.P., Marras, C., Hazrati, L.N., Liu, L.W., Lang, A.E., 2014. Alimentary, my dear 
Watson? The challenges of enteric alpha -synuclein as a Parkinson's disease biomarker. Movement 
disorders : official journal of the Movement Disorder Society 2 9, 444 -450. 
Yeung, T., Gilbert, G.E., Shi, J., Silvius, J., Kapus, A., Grinstein, S., 2008. Membrane 
phosphatidylserine regulates surface charge and protein localization. Science 319, 210 -213. 
Zangaglia, R., Martignoni, E., Glorioso, M., Ossola, M., Ribold azzi, G., Calandrella, D., Brunetti, 
G., Pacchetti, C., 2007. Macrogol for the treatment of constipation in Parkinson's disease. A 
randomized placebo -controlled study. Movement disorders : official journal of the Movement 
Disorder Society 22, [ADDRESS_334436] -
spectrum systemic antiviral agent with therapeutic potential. Proce edings of the National Academy 
of Sciences of the [LOCATION_002] of America 108, [ZIP_CODE] -[ZIP_CODE].  
 
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  75 
 APPENDIX 1 :  CLINICAL LABORATORY DETERMINATION  
Hematology  Serum chemistry  Urine analysis 
(dipstick)  
Full and differential blood 
count  
Hematocrit (Hct)  
Hemoglobin (Hb)  
Mean corpuscular hemoglobin 
(MCH)  
Mean corpuscular hemoglobin 
concentration (MCHC)  
Mean corpuscular volume 
(MCV)  
Platelet count  
Red blood cell (RBC) count  
White blood cell (WBC) count 
with differential  
 Albumin  
Alanine aminotransferase (A LT) 
Alkaline phosphatase (ALP)  
Aspartate aminotransferase (AST)  
Blood Urea Nitrogen (BUN) or 
Urea  
Carbon dioxide (CO 2) 
Creatinine  
Creatine kinase and subtypes  
Electrolytes (Na, K, Cl, Ca, P)  
Gamma --glutamyl transpeptidase 
(GGT)  
Glucose  
Lactate dehydrogena se (LDH)?  
Total bilirubin  
Direct bilirubin  
Total cholesterol  
Triglycerides  Appearance  
pH 
Protein  
Glucose  
Ketone bodies  
Indicators of blood 
and WBCs  
Specific gravity  
Urine human 
chorionic 
gonadotropin (HCG) 
(pre-menopausal 
females only)  
Urobilinogen  
Coagulation    
Prothrombin time (PT)  
Activated partial 
thromboplastin time (PTT)    
Pregnancy test: A pregnancy test will be performed on all female patients of child -bearing 
potential at the screening visit.  
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  76 
  
 
APPEN DIX  2: SCHEDULE S OF EVENTS  
 
STAGE 1  
 
Period  1 
Run-In 
Sentinel  
2 wks  2.1 
Single  
Dose  
3-8 wks  2.2 
Wash -Out 
2 wks  
 D1 D14 D1  
Consent  x    
Demographics  x    
Inclusion/exclusion  x x   
Medical history  x    
Physical exam  x  x x 
Vital signs1 x  x x 
Rome -IV x    
Blood chemistry  x  x x 
Hematology  x    
Urinalysis  x   x 
Fecal occult blood  x  x x 
EKG  x  x x 
Pregnancy test  x    
Monitoring    x x 
Discontinue medications  x    
Re-start medications     x 
Diary entries  x x x x 
UPDRS  x  X4 x2 
I-Button3 x x X  
PAC -QOL  x x X4 x2 
PAC_SYM  x x X4 x2 
RBDQ  x  X4 x2 
NMSQ  x  X4 x2 
PFS-16 x  X4 x2 
UM-PDHQ  x  X4 x2 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334437] -dose  
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  78 
 STAGE 2  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334438] -dose PK draw.  
6Visit 3 occurs on the day before randomization in non -PK subjects.

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  1 
 APPEN DIX 3: NUMERIC RATING SCALE S FOR PAIN AND SWELL ING  
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  2 
 APPENDIX 4: ROME -IV CRITERIA FOR CONSTIPATION  
 
Must include two or more of the following:  
Straining during at least 25% of defecations  
Lumpy or hard stools in at least 25% of defecations  
Sensation of incomplete evacuation for at least 25% of defecations  
Sensation of incomplete evacuation for at least 25% of defecations  
Sensation of anorectal obstruction/block age for at least 25% of defecations  
Manual maneuvers to facilitate at least 25%of defecations (e.g., digital evacuation, support of the 
pelvic floor)  
Fewer than three defecations per week  
Loose stools are rarely present without the use of laxatives  
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  3 
 APPENDIX 5: EASE OF EVACUATION SCALE  
 
 
1.Manual disimpaction  
2.Enema needed  
3.Straining needed  
4.Normal  
5.Urgent without pain  
6.Urgent with pain  
7.Incontinent  
 
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  4 
  
APPENDIX 6: BRISTOL STOOL CHART  
 
The assessment of stool consistency is a validated surrogate of intestinal motility  (Lewis and 
Heaton, 1997 ). We have chosen the Bristol Stool Chart as a patient -friendly means of categorizing 
stool characteristics .  
 
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  5 
 APPENDIX 7: SLEEP DIARY  
Participants will complete a sleep diary on a daily basis throughout the study.   
The diaries will include  time into  bed and estimated time to sleep  as well as wake time and duration 
during the night .  
An example of the sleep diary is shown below:  
Date  Dose 
(mg)  Time 
to bed 
(hr) Sleep 
onset 
(hr) Morning 
awakeni
ng (hr) Wakes at 
night/ 
duration 
(min)  Total 
Hours 
sleep  Leg 
thrashi
ng/screa
ming/vi
vid 
dreams  I-Button  
on 
3/20 - 12 1.30 7.0 2 (30min  
each) 4.5 Yes No 
3/21 100 12 1.0 7.0 1 (60 min)  5.0 Some  Yes,  
3/22 100 11 12.30  7.30 2 (60 min, 
60min)  5.0 Yes Yes,  
3/23 100 12 12.30  6.30 1 (30min)  5.5 Some  Yes,  
3/24 150 - 11.0 7.30 1 (30min)  8.0 No Yes,  
3/25 150 - 11.0 7.0 - 8.0 No Yes,  
 
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  6 
 APPENDIX 8 : I-BUTTON  
The I-Button  is a small rugged self -sufficient system that measures temperature and records 
the results in a protected memory section.  The Thermochron I-Button  DS1921H ( Maxim 
Integrated, Dallas TX ) used for skin  temperature measurement .  The I -Button DS1921H is 
regula ted by F ederal Communications Commission (FCC) as a class B digital radiofrequency 
device that is an unintentional radiator (i.e., CFR 47, Part 15, Subpart B), and conforms to the 
national standards  tested under ANSI C63.4 -2001 . The  I-Button is composed o f a semiconductor 
temperature  sensor, a real timer, a memory and a lithium battery, all enclosed in  a 16-mm diameter 
by 6-mm thick cylinder. Manufacturing specifications  include: temperature range from +15 to +46 
°C, and 1 °C of  accuracy with a precision o f 0.125 °C. The memory (NV RAM) allows it  to record 
up to [ADDRESS_334439] band using  Velcro®, with 
the sensor face of the I-Button  being placed over the  inside of the wrist, on the radial artery of the 
dominant hand.    Subjects will remove  and replace the data logger when necessary (i.e., to have a 
bath or shower).  After the period of moni toring, the information stored in the I-Button  will be 
transferred through an adapter (DS1402D -DR8, IDC, Spain) to a personal computer  using I-Button  
Viewer v. 3.22© 1992 –2005 Dallas Semiconductor  MAXIM software provided by [CONTACT_13989]. The value of s kin temperature assessment in sleep research is that the endogenous 
skin warming resulting from increased skin blood flow is functionally linked to sleep propensity 
(Sarabia et al., 2008 ; van Marken Lichtenbelt et al., 2006 ). 
      From the collected data we will calculate the mesor, amplitude, acrophase  (time of peak 
temperature) , Rayleigh test (an index of interdaily stability), mean waveforms  (averaged per 
subject, and then for each experimental group) using an analysis package for temporal series. 
Briefly, interdaily phase stability will be calculated as follows: firstly, daily acrophases for subjects 
at baseline and following treatment will be obtained using least -squares data fitting to a cosine 
function with a period  of [ADDRESS_334440]  (CircStat : Matlab  toolbox for circular  statistical package) . This test provides 
an r vector  with its  origin at the center of a circumference of radius one. The r vector length  
(between 0 and 1) is p roportional to the degree of phase homogeneity  during the period analyzed, 
and can be considered to be a  measure of the  rhythm's phase stability during successive days.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334441] repeated 
measures ANOVA (Sarabia et al., 2008 ). 
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  8 
 APPENDIX  9: NON -MOTOR SYMPTOMS QUESTIONNAIRE (NMSQ)  
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  9 
 APPENDIX 10: BECK DEPRESSION INVENTORY  (BDI)  
 
1.  
0 I do not feel sad.  
1 I feel sad  
2 I am sad all the time and I can't snap out of it.  
3 I am so sad and unhappy that I can't stand it.  
2.  
[ADDRESS_334442] failed more than the average person.  
2 As I look back on my life, all I can see is a lot of failures.  
3 I feel I am a complete failure as a person .  
4.  
0 I get as much satisfaction out of things as I used to.  
1 I don't enjoy things the way I used to.  
2 I don't get real satisfaction out of anything anymore.  
3 I am dissatisfied or bored with everything.  
5. 
0 I don't feel particularly guilty  
[ADDRESS_334443] of the time.  
3 I feel guilty all of the time.  
6.  
0 I don't feel I am being punished.  
1 I feel I may be punished.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334444] to be punished.  
3 I feel I am being punished.  
7.  
0 I don't feel disappointed in myself.  
1 I am disappointed in myself.  
2 I am disgusted with myself.  
3 I hate myself.  
8.  
0 I don't feel I am any worse than anybody else.  
1 I am critical of myself for my weaknesses or mistakes.  
2 I blame myself all the  time for my faults.  
3 I blame myself for everything bad that happens.  
9.  
0 I don't have any thoughts of killing myself.  
[ADDRESS_334445] thoughts of killing myself, but I would not carry them out.  
2 I would like to kill myself.  
3 I would kill myself if I ha d the chance.  
10.  
0 I don't cry any more than usual.  
1 I cry more now than I used to.  
2 I cry all the time now.  
3 I used to be able to cry, but now I can't cry even though I want to.  
11.  
[ADDRESS_334446] in other people.  
1 I am less interested in other people than I used to be.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334447] greater difficulty in making decisions mor e than I used to.  
3 I can't make decisions at all anymore.  
14.  
0 I don't feel that I look any worse than I used to.  
[ADDRESS_334448] to do anything.  
3 I can't do any work at all.  
16.  
0 I can sleep as well as usual.  
1 I don't sleep as well as I used to.  
[ADDRESS_334449] to get back to sleep.  
3 I wake up several hours earlier than I used to and cannot get back to sleep.  
17.  
0 I don't get more tired than usual.  
[ADDRESS_334450] anything.  
3 I am too tired to do anything.  
 
18.  
0 My appetite is no worse than usual.  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  [ADDRESS_334451] no appetite at all anymore.  
19.  
0 I haven't lost much weight, if any, lately.  
[ADDRESS_334452] more than fifteen pounds.  
20.  
0 I am no more w orried about my health than usual.  
1 I am worried about physical problems like aches, pains, upset stomach, or constipation.  
2 I am very worried about physical problems and it's hard to think of much else.  
[ADDRESS_334453] would be zero. This 
would mean you circles zero on each question. You can evaluate y our depression according to the 
Table below. Total Score____________________  
Levels of Depression 1 -10____________________These ups and downs are considered normal  
11-16___________________ Mild mood disturbance  
17-20___________________Borderline clinical  depression  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  13 
 21-30___________________Moderate depression  
31-40___________________Severe depression  
over 40__________________Extreme depression  
  
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  14 
 APPENDIX 11: UNIFIED  PARKINSON’S DISEASE RATING SCALE  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  15 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  16 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  17 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  18 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  19 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  20 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  21 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  22 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  23 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  24 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  25 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  26 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  27 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  28 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  29 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  30 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  31 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  32 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  33 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  34 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  35 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  36 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  37 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  38 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  39 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  40 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  41 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  42 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  43 
 APPENDIX 12: MINI MENTAL STATE EXAMINATION  
 
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  44 
 APPENDIX 13 : TRAIL MAKING A & B  
 
 
 
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  45 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  46 
  
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  47 
 APPENDIX 14: UM-PDHQ  
 
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  48 
  
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  49 
 APPENDIX 1 5: PARKINSON ’S DISEASE FATIGUE SC ALE (PFS -16) 
 
 
 
 
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  50 
  
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  51 
 APPENDIX 16: PATIENT ASSESSMENT OF  CONSTIPATION SYMPTO MS 
 
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  52 
 APPENDIX 17 : PATIENT ASSESSMENT OF  CONSTIPATION QUALIT Y OF LIFE   
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  53 
 

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  54 
  
  

  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  55 
 APPENDIX 18: REM SLEEP BEHAVIOR DISORDER  SCREENING 
QUESTIONNAIRE  
 
1. I sometimes have very vivid dreams. yes/no  
2. My dreams frequently have an aggressive or action -packed content. yes/no  
3. The dream contents mostly match my nocturnal behavior. yes/no  
4. I know that my arms or legs move when I sleep. yes/no  
5. It thereby [CONTACT_273768] I (almost) hurt my bed part ner or myself. yes/no  
6. I have or had the following phenomena during my dreams:  
6.1. Speaking, shouting, swearing, laughing loudly yes/no  
6.2. Sudden limb movements, “fights” yes/no  
6.3. Gestures, complex movements, that are useless during sleep, e.g. , to wave, to salute, 
to frighten mosquitoes, fall off the bed yes/no  
6.4. Things that fell down around the bed, e.g., bedside lamp, book, glasses yes/no  
7. It happens that my movements awake me. Yes/no  
8. After awakening I mostly remember the content o f my dreams well. Yes/no  
9. My sleep is frequently disturbed. Yes/no  
10. I have/had a disease of the nervous system (e.g., stroke, head trauma, Parkinsonism, RLS, 
narcolepsy, depression, epi[INVESTIGATOR_002], inflammatory disease of the brain), which? yes/no   
   
  
 
 
 
CP1001  v0.9,  Version Date: 27JUL2017  56 
 APP ENDIX 19: PARKINSON’S DISEASE SLEEP SCALE  
 
 
